<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1005200077
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Dovato
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LAMIVUDINE,DOLUTEGRAVIR SODIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        300,52.6
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2885.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GLAXOSMITHKLINE (GSK)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GLAXOSMITHKLINE (GSK)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Glaxo Saudi Arabia Ltd.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>infection: dolutegravir and lamivudine. Dolutegravir belongs to a group of anti-retroviral medicines called <em>integrase inhibitors </em>(INIs), and lamivudine belongs to a group of anti-retroviral medicines called <em>nucleoside </em><em>analogue</em><em> reverse transcriptase inhibitors </em>(NRTIs).</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Dovato is used to treat HIV in adults and adolescents over 12&nbsp;years old who weigh at least 40&nbsp;kg.</p><p>&nbsp;</p><p>Dovato does not cure HIV infection; it keeps the amount of virus in your body at a low level. This helps maintain the number of CD4 cells in your blood. CD4 cells are a type of white blood cells that are important in helping your body to fight infection.</p><p>&nbsp;</p><p>Not everyone responds to treatment with Dovato in the same way. Your doctor will monitor the effectiveness of your treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Dovato:</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-no-proof:yes'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_a9cf55d7-e6fa-419d-994e-767f86b15454 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-no-proof:yes'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are <strong>allergic</strong> (<em>hypersensitive</em>) to dolutegravir or lamivudine or any of the other ingredients of this medicine (listed in section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking a medicine called fampridine (also known as dalfampridine; used in multiple sclerosis).</p><p>&nbsp;</p><p>&reg; If you think any of these apply to you, <strong>tell your doctor</strong>.</p><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-no-proof:yes'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_b8dc43a6-dc7c-49a5-8519-4536b5b512ae \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-no-proof:yes'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>Some people taking Dovato or other combination treatments for HIV are more at risk of serious side effects than others. You need to be aware of the extra risks:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have moderate or severe liver disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever had liver disease, including hepatitis B or C (if you have hepatitis B infection, don&rsquo;t stop Dovato without your doctor&rsquo;s advice, as your hepatitis may come back)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a kidney problem.</p><p>&reg;<strong> </strong><strong>Talk to your doctor before using Dovato </strong>if any of these apply to you. You may need extra check-ups, including blood tests, while you&rsquo;re taking your medicine. See section 4 for more information.</p><p>&nbsp;</p><p><u>Allergic reactions</u></p><p>Dovato contains dolutegravir. Dolutegravir can cause a serious allergic reaction known as a <em>hypersensitivity reaction</em>. You need to know about important signs and symptoms to look out for while you&rsquo;re taking Dovato.</p><p>&reg; <strong>Read the information</strong> &lsquo;Allergic reactions&rsquo; in section 4 of this leaflet.</p><p><u>&nbsp;</u></p><p><u>Look out for important symptoms</u></p><p>Some people taking medicines for HIV infection develop other conditions, which can be serious. These include:<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;mso-no-proof:yes'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_043da49b-9019-4d10-a1e0-4b088f7d8ee8
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;mso-no-proof:yes'><span style='mso-element:
field-end'></span></span><![endif]--></p><ul><li>symptoms of infections and inflammation</li><li>joint pain, stiffness and bone problems.</li></ul><p>You need to know about important signs and symptoms to look out for while you&rsquo;re taking Dovato.<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_4e432257-6e29-48fd-82b4-0a1b873648fb \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&reg; <strong>Read the information &lsquo;Other possible side effects&rsquo; in section 4 </strong>of this leaflet.<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_a2d1a781-2dc2-4264-a701-f609b42fadbd \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>This medicine is not for use in children under 12&nbsp;years of age and in adolescents weighing less than 40&nbsp;kg, because it has not been studied in these patients.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Dovato</strong></p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>Don&#39;t take Dovato with the following medicine:</p><ul><li>fampridine (also known as dalfampridine), used in <strong>multiple sclerosis.</strong></li></ul><p>&nbsp;</p><p>Some medicines can affect how Dovato works or make it more likely that you will have side effects. Dovato can also affect how some other medicines work.</p><p><strong>Tell your doctor </strong>if you are taking any of the medicines in the following list:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; metformin, to treat <strong>diabetes</strong></p><ul><li>medicines called <strong>antacids</strong>, to treat <strong>indigestion</strong> and <strong>heartburn. Do not take an antacid </strong>during the 6&nbsp;hours before you take Dovato, or for at least 2&nbsp;hours after you take it (see also section&nbsp;3, &lsquo;How to take Dovato&rsquo;)</li><li>supplements or multivitamins containing calcium, iron or magnesium.<strong> If you take Dovato with food, </strong>you can take supplements or multivitamins containing calcium, iron or magnesium at the same time as Dovato. <strong>If you do not take Dovato with food, do not take a supplement or multivitamin containing calcium, iron or magnesium </strong>during the 6&nbsp;hours before you take Dovato, or for at least 2&nbsp;hours after you take it (see also section 3,<em> </em>&lsquo;How to take Dovato&rsquo;)</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; emtricitabine, etravirine, efavirenz, nevirapine or tipranavir/ritonavir, to treat <strong>HIV infection</strong></p><ul><li>medicines (usually liquids) containing sorbitol and other sugar alcohols (such as xylitol, mannitol, lactitol or maltitol), if taken regularly</li><li>cladribine, to treat <strong>leukaemia</strong> or <strong>multiple sclerosis</strong></li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin, to treat tuberculosis (TB) and other <strong>bacterial infections</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phenytoin and phenobarbital, to treat <strong>epilepsy</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oxcarbazepine and carbamazepine, to treat <strong>epilepsy </strong>or <strong>bipolar disorder</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>St. John&rsquo;s wort </strong>(<em>Hypericum perforatum</em>), a herbal remedy to treat <strong>depression.</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &reg; <strong>Tell your doctor or pharmacist</strong> if you are taking any of these. Your doctor may decide to adjust your dose or that you need extra check-ups.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Pregnancy</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-no-proof:yes'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_718cc344-9398-4287-9926-6c09f7998445 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-no-proof:yes'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>If you are pregnant, think you may be pregnant, or if you are planning to have a baby:<!--[if supportFields]><span style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_8414e282-1d75-4677-b88e-25cb1d5a575c \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>&reg;</strong><strong> Talk to your doctor </strong>about the risks and benefits of taking Dovato<strong>.</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_1f620981-fdee-43b5-b0b2-d2f974a7446b \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>&nbsp;</p><p>Tell your doctor immediately if you become pregnant or are planning to become pregnant. Your doctor will review your treatment. Do not stop taking Dovato without consulting your doctor, as this may harm you and your unborn child.</p><p><strong>&nbsp;</strong></p><p><strong>Breast-feeding</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_36eef9ce-696d-4b0d-943d-bcaec92b9b97 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>Breast-feeding is not </strong>recommended in women living with HIV because HIV infection can be passed on to the baby in breast milk.<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_3a4eec1b-297f-47c1-a383-3717d18134ec \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>A small amount of the ingredients in Dovato can also pass into your breast milk.<!--[if supportFields]><span style='mso-bidi-font-size:11.0pt'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_702925ef-0c9c-4be0-8791-fd76c826cccb \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>If you are breast-feeding, or thinking about breast-feeding, you should <strong>discuss it with</strong> <strong>your doctor as soon as possible.</strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_cae59942-0d15-4f5d-ab50-e9516471cf53 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>&nbsp;</p><p><strong>Driving and using machines</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-no-proof:yes'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_e5af408b-69b5-4bfa-b202-a4684c27646d \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-no-proof:yes'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Dovato can make you dizzy and have other side effects that make you less alert.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &reg; Don&rsquo;t drive or operate machinery unless you are sure you&rsquo;re not affected.<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_3b0dfa58-c97b-4b9b-8029-de3a2b3fe949 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><strong>Dovato contains sodium</strong></p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p><!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p><!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><ul><li>The recommended dose of Dovato is<strong> one tablet once a day.</strong></li></ul><p>&nbsp;</p><p>Swallow the tablet with some liquid. Dovato can be taken with or without food.</p><p>&nbsp;</p><p><strong>Use in adolescents</strong></p><p>Adolescents aged between 12 and 17&nbsp;years and weighing at least 40&nbsp;kg can take the adult dose of one tablet once a day.</p><p>&nbsp;</p><p><strong>Antacid medicines</strong></p><p>Antacids, to treat indigestion and heartburn, can stop Dovato being absorbed into your body and make it less effective.</p><p>Do not take an antacid during the 6&nbsp;hours before you take Dovato, or for at least 2&nbsp;hours after you take it. You can take other acid-lowering medicines like ranitidine and omeprazole at the same time as Dovato.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &reg; Talk to your doctor for further advice on taking acid-lowering medicines with Dovato.</p><p><strong>&nbsp;</strong></p><p><strong>Supplements or multivitamins containing calcium, iron or magnesium</strong></p><p>Supplements or multivitamins containing calcium, iron or magnesium can stop Dovato being absorbed into your body and make it less effective.</p><p>If you take Dovato with food, you can take supplements or multivitamins containing calcium, iron or magnesium at the same time as Dovato. If you do not take Dovato with food, do not take a supplement or multivitamin containing calcium, iron or magnesium during the 6&nbsp;hours before you take Dovato, or for at least 2&nbsp;hours after you take it.</p><p>&reg; Talk to your doctor for further advice on taking supplements or multivitamins containing calcium, iron or magnesium with Dovato.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>If you take more Dovato than you should</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-no-proof:yes'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_5ac903f3-307b-4e66-bdb6-5465a2a04049 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-no-proof:yes'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>If you take too many tablets of Dovato <strong>contact your doctor or pharmacist </strong><strong>for advice.</strong> If possible, show them the Dovato pack.<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;mso-no-proof:yes'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_cf7a02b6-98de-43b6-82fe-f3c96f33e84e
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;mso-no-proof:yes'><span style='mso-element:
field-end'></span></span><![endif]--></p><p><strong>If you forget to take Dovato</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-no-proof:yes'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_8ee1b8e0-2c6e-4b16-90b7-ed4c184644f0 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-no-proof:yes'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>If you miss a dose, take it as soon as you remember. But if your next dose is due within 4 hours, skip the dose you missed and take the next one at the usual time. Then continue your treatment as before.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &reg;<strong>Do not take a double dose</strong> to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>Don&rsquo;t stop taking Dovato without advice from your doctor</strong><!--[if supportFields]><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:11.0pt;mso-no-proof:yes'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_ff74c27c-8234-42bb-9b07-567b81405d66
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-no-proof:yes'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Take Dovato for as long as your doctor recommends. Don&rsquo;t stop unless your doctor tells you to. Stopping Dovato can affect your health and how future treatment works.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them, <strong>so it is very important to talk to your doctor about any changes in your health</strong>.</p><p>&nbsp;</p><p><strong>Allergic reactions</strong></p><p>Dovato contains dolutegravir. Dolutegravir can cause a serious allergic reaction known as a <em>hypersensitivity reaction</em>. This is an uncommon reaction (may affect up to 1 in 100 people) in people taking dolutegravir. If you get any of the following symptoms:</p><p>&middot;&nbsp;&nbsp; skin rash</p><p>&middot;&nbsp;&nbsp; a high temperature (<em>fever</em>)</p><p>&middot;&nbsp;&nbsp; lack of energy (<em>fatigue</em>)</p><p>&middot;&nbsp;&nbsp; swelling, sometimes of the face or mouth (<em>angioedema</em>), causing difficulty in breathing</p><p>&middot;&nbsp;&nbsp; muscle or joint aches.</p><p><strong>&reg;</strong><strong> </strong><strong>See a doctor straight away. </strong>Your doctor may decide to carry out tests to check your liver, kidneys or blood, and may tell you to stop taking Dovato.</p><p>&nbsp;</p><p><strong>Very common side effects</strong></p><p>These may affect <strong>more than 1 in 10 </strong>people:</p><p>&middot;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp; feeling sick (<em>nausea</em>).</p><p>&nbsp;</p><p><strong>Common side effects</strong></p><p>These may affect <strong>up to 1 in 10</strong> people:</p><p>&middot;&nbsp;&nbsp; depression (feelings of deep sadness and unworthiness)</p><p>&middot;&nbsp;&nbsp; rash</p><p>&middot;&nbsp;&nbsp; itching (<em>pruritus</em>)</p><p>&middot;&nbsp;&nbsp; being sick (<em>vomiting</em>)</p><p>&middot;&nbsp;&nbsp; stomach (<em>abdominal</em>) pain or discomfort</p><p>&middot;&nbsp;&nbsp; weight gain</p><p>&middot;&nbsp;&nbsp; wind (<em>flatulence</em>)</p><p>&middot;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp; feeling drowsy</p><p>&middot;&nbsp;&nbsp; difficulty sleeping (<em>insomnia</em>)</p><p>&middot;&nbsp;&nbsp; abnormal dreams</p><p>&middot;&nbsp;&nbsp; lack of energy (<em>fatigue</em>)</p><p>&middot;&nbsp;&nbsp; hair loss</p><p>&middot;&nbsp;&nbsp; anxiety</p><p>&middot;&nbsp;&nbsp; joint pain</p><p>&middot;&nbsp;&nbsp; muscle pain.</p><p>&nbsp;</p><p>Common side effects that may show up in blood tests are:</p><p>&middot;&nbsp;&nbsp; increase in the level of liver enzymes (<em>aminotransferases</em>)</p><p>&middot;&nbsp;&nbsp; increase in the level of enzymes produced in the muscles (<em>creatine phosphokinase</em>).</p><p>&nbsp;</p><p><strong>Uncommon side effects</strong></p><p>These may affect <strong>up to 1 in 100 </strong>people:</p><p>&middot;&nbsp;&nbsp; inflammation of the liver (<em>hepatitis</em>)</p><p>&middot;&nbsp;&nbsp; suicidal attempt (particularly in patients who have had depression or mental health problems before)</p><p>&middot;&nbsp;&nbsp; suicidal thoughts (particularly in patients who have had depression or mental health problems before).</p><p>&middot;&nbsp;&nbsp; panic attack</p><p><strong>&nbsp;</strong></p><p>Uncommon side effects that may show up in blood tests are:</p><p>&middot;&nbsp;&nbsp; a decreased number of cells involved in blood clotting (<em>thrombocytopenia</em>)</p><p>&middot;&nbsp;&nbsp; a low red blood cell count (<em>anaemia</em>) or low white blood cell count (<em>neutropenia</em>).</p><p><strong>&nbsp;</strong></p><p><strong>Rare side effects</strong></p><p>These may affect <strong>up to 1 in 1000 </strong>people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver failure (signs may include yellowing of the skin and the whites of the eyes or unusually dark urine)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling, sometimes of the face or mouth (<em>angioedema</em>), causing difficulty in breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the pancreas (<em>pancreatitis</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breakdown of muscle tissue.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; suicide (particularly in patients who have had depression or mental health problems before)</p><p>&nbsp;</p><p>&reg;<strong> </strong><strong>&nbsp;Tell your doctor immediately</strong> if you experience any mental health problems (see also other mental health problems above).</p><p><strong>&nbsp;</strong></p><p>Rare side effects that may show up in blood tests are:</p><p>&middot;&nbsp;&nbsp; increase in bilirubin (a test of liver function)</p><p>&middot;&nbsp;&nbsp; increase in an enzyme called <em>amylase</em>.</p><p><strong>&nbsp;</strong></p><p><strong>Very rare side effects</strong></p><p>These may affect <strong>up to 1 in 10,000 </strong>people:</p><p>&middot;&nbsp;&nbsp; lactic acidosis (excess lactic acid in the blood)</p><p>&middot;&nbsp;&nbsp; numbness, tingly feelings in the skin (pins and needles)</p><p>&middot;&nbsp;&nbsp; sensation of weakness in the limbs.</p><p><strong>&nbsp;</strong></p><p>Very rare side effects that may show up in blood tests are:</p><p>&middot;&nbsp;&nbsp; a failure of the bone marrow to produce new red blood cells (<em>pure red cell aplasia</em>).</p><p><strong>&nbsp;</strong></p><p><strong>Other possible side effects</strong></p><p>People taking combination therapy for HIV may get other side effects.</p><p>&nbsp;</p><p><strong>Symptoms of infection and inflammation </strong></p><p>People with advanced HIV infection or AIDS have weak immune systems and are more likely to develop serious infections (opportunistic infections). Such infections may have been &ldquo;silent&rdquo; and not detected by the weak immune system before treatment was started. After starting treatment, the immune system becomes stronger, and may attack the infections, which can cause symptoms of infection or inflammation. Symptoms usually include fever, plus some of the following:</p><p>&middot;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp; stomach ache</p><p>&middot;&nbsp;&nbsp; difficulty breathing.</p><p>&nbsp;</p><p>In rare cases, as the immune system becomes stronger, it can also attack healthy body tissue (<em>autoimmune disorders</em>). The symptoms of autoimmune disorders may develop many months after you start taking medicine to treat your HIV infection. Symptoms may include:</p><p>&middot;&nbsp;&nbsp; palpitations (rapid or irregular heartbeat) or tremor</p><p>&middot;&nbsp;&nbsp; hyperactivity (excessive restlessness and movement)</p><p>&middot;&nbsp;&nbsp; weakness beginning in the hands and feet and moving up towards the trunk of the body.</p><p><strong>&nbsp;</strong></p><p><strong>If you get any symptoms of infection</strong> or if you notice any of the symptoms above:</p><p><strong>&reg;</strong><strong> </strong><strong>Tell your doctor immediately</strong>. Don&rsquo;t take other medicines for the infection without your doctor&rsquo;s advice.</p><p>&nbsp;</p><p><strong>Joint pain, stiffness and bone problems</strong></p><p>Some people taking combination therapy for HIV develop a condition called <em>osteonecrosis</em>. With this condition, parts of the bone tissue are permanently damaged because of reduced blood supply to the bone. People may be more likely to get this condition:</p><p>&middot;&nbsp;&nbsp; if they have been taking combination therapy for a long time</p><p>&middot;&nbsp;&nbsp; if they are also taking anti-inflammatory medicines called corticosteroids</p><p>&middot;&nbsp;&nbsp; if they drink alcohol</p><p>&middot;&nbsp;&nbsp; if their immune systems are very weak</p><p>&middot;&nbsp;&nbsp; if they are overweight.</p><p>&nbsp;</p><p><strong>Signs of osteonecrosis include:</strong></p><p>&middot;&nbsp;&nbsp; stiffness in the joints</p><p>&middot;&nbsp;&nbsp; aches and pains in the joints (especially in the hip, knee or shoulder)</p><p>&middot;&nbsp;&nbsp; difficulty moving.</p><p>If you notice any of these symptoms:</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>&reg;</strong><strong> </strong><strong>Tell your doctor.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Weight, blood lipid and blood glucose effects: </strong></p><p>During HIV therapy there may be an increase in weight and in levels of blood lipids and glucose. This is partly linked to restored health and lifestyle, and sometimes to the HIV medicines themselves. Your doctor will test for these changes.</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-no-proof:yes'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_6b9ba2c1-7d4e-4a27-9e8e-c5215595f5e8 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
mso-no-proof:yes'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and bottle after EXP. The expiry date refers to the last day of that month.</p><p>Do not store Dovato above 30 &deg;C</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What </strong><strong>Dovato contains </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; The active substances are dolutegravir and lamivudine. Each tablet contains dolutegravir sodium equivalent to 50&nbsp;mg dolutegravir and 300&nbsp;mg lamivudine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are microcrystalline cellulose, sodium starch glycolate, magnesium stearate, mannitol (E421), povidone (K29/32) and sodium stearyl fumarate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Dovato film-coated tablets are oval, biconvex, white, film-coated tablets debossed with 'SV 137' on one face.
	
	The film-coated tablets are provided in bottles closed with child-resistant closures.
	
	Each bottle contains 30 film-coated tablets.
Not all pack sizes may be available in your country.
	

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>MANUFACTURED BY:</strong></p><p>GlaxoSmithKline LLC, Zebulon, North Carolina, USA</p><p><strong>PACKED BY:</strong></p><p>Glaxo Wellcome, S.A.*, Aranda, Spain</p><p><strong>MARKETING AUTHORISATION HOLDER:</strong></p><p>Glaxo Saudi Arabia Ltd.* Jeddah, KSA</p><p>*member of the GlaxoSmithKline group of companies</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Version number: EMEAv20  
Date of issue: 31 October 2024

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">دوڤاتو هو دواء يحتوي على مادتين فعالتين يُستخدمان لعلاج عدوى فيروس نقص المناعة البشرية: دولوتيجراڤير ولاميڤودين. ينتمي دولوتيجراڤير إلى فئة من الأدوية المضادة للفيروسات الرجعية تُسمى <em>مثبطات إنزيم الإنتيغراز</em> (INIs)، وينتمي لاميڤودين إلى فئة من الأدوية المضادة للفيروسات الرجعية تُسمى <em>الأدوية النيوكليوزيدية المضادة لإنزيم المنتسخة العكسية</em> (NRTI).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم دوڤاتو في علاج فيروس نقص المناعة البشرية لدى البالغين والمراهقين الذين تزيد أعمارهم عن 12&nbsp;عامًا، والذين لا يقل وزنهم عن 40&nbsp;كجم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يُشفي دوڤاتو تمامًا من عدوى نقص المناعة البشرية؛ وإنما يُبقي مقدار الفيروس في الجسم منخفضًا. وهذا يحافظ على عدد خلايا CD4 (كتلة التمايز 4) المناعية في الدم. وخلايا CD4 (كتلة التمايز 4) هي نوع من خلايا الدم البيضاء التي لها دور مهم في مساعدة الجسم على مكافحة العدوى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وتختلف استجابة المرضى للعلاج بعقار دوڤاتو. سوف يراقب طبيبك مدى فعالية علاجك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول </strong><strong>دوڤاتو</strong><strong>:</strong><!--[if supportFields]><b><span lang=AR-SA style='font-family:
"Times New Roman",serif;mso-ascii-font-family:"Times New Roman Bold";
mso-fareast-font-family:"Times New Roman";mso-hansi-font-family:"Times New Roman Bold";
mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span> </span></b><b><span
dir=LTR style='font-family:"Times New Roman Bold",serif;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:"Times New Roman";mso-ansi-language:
EN-GB'>DOCVARIABLE</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='font-family:"Times New Roman",serif;mso-ascii-font-family:"Times New Roman Bold";
mso-fareast-font-family:"Times New Roman";mso-hansi-font-family:"Times New Roman Bold";
mso-ansi-language:EN-GB'><span dir=RTL></span><span dir=RTL></span> </span></b><b><span
dir=LTR style='font-family:"Times New Roman Bold",serif;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:"Times New Roman";mso-ansi-language:
EN-GB'>VAULT_ND_94ad35ee-d7c3-412b-904f-20e3d171b2de \* MERGEFORMAT</span></b><span
dir=RTL></span><span dir=RTL></span><b><span style='font-family:"Times New Roman",serif;
mso-ascii-font-family:"Times New Roman Bold";mso-fareast-font-family:"Times New Roman";
mso-hansi-font-family:"Times New Roman Bold";mso-ansi-language:EN-GB'><span
dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span style='mso-element:
field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-family:"Times New Roman",serif;mso-ascii-font-family:
"Times New Roman Bold";mso-fareast-font-family:"Times New Roman";mso-hansi-font-family:
"Times New Roman Bold";mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">&middot;&nbsp;&nbsp; إذا كنت تعاني من <strong>حساسية</strong> (<em>فرط الحساسية</em>) لدولوتيجراڤير أو لاميڤودين أو أيٍّ من المكوّنات الأخرى لهذا الدواء (المذكورة في القسم رقم 6).</p><p dir="RTL">&middot;&nbsp;&nbsp; إذا كنت تتناول دواء اسمه <strong>فامبريدين</strong> (المعروف أيضًا بدالفامبريدين، والمستخدم في علاج مرض التصلب المتعدد).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&not; إذا كنت تعتقد أن أياً من هذه الحالات تنطبق عليك، <strong>فاستشر طبيبك</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-family:"Times New Roman",serif;mso-ascii-font-family:
"Times New Roman Bold";mso-fareast-font-family:"Times New Roman";mso-hansi-font-family:
"Times New Roman Bold";mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>
</span></b><b><span dir=LTR style='font-family:"Times New Roman Bold",serif;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
mso-ansi-language:EN-GB'>DOCVARIABLE</span></b><span dir=RTL></span><span
dir=RTL></span><b><span style='font-family:"Times New Roman",serif;mso-ascii-font-family:
"Times New Roman Bold";mso-fareast-font-family:"Times New Roman";mso-hansi-font-family:
"Times New Roman Bold";mso-ansi-language:EN-GB'><span dir=RTL></span><span
dir=RTL></span> </span></b><b><span dir=LTR style='font-family:"Times New Roman Bold",serif;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
mso-ansi-language:EN-GB'>VAULT_ND_a1bc15e6-d103-4e15-acc0-97e44bcf64de \*
MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='font-family:"Times New Roman",serif;mso-ascii-font-family:"Times New Roman Bold";
mso-fareast-font-family:"Times New Roman";mso-hansi-font-family:"Times New Roman Bold";
mso-ansi-language:EN-GB'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-family:"Times New Roman",serif;mso-ascii-font-family:
"Times New Roman Bold";mso-fareast-font-family:"Times New Roman";mso-hansi-font-family:
"Times New Roman Bold";mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">بعض المرضى الذين يتناولون دوڤاتو أو غيره من العلاجات المركبة لفيروس نقص المناعة البشرية يكونون أكثر عُرضة للإصابة بالآثار الجانبية الخطيرة مقارنةً بغيرهم. يجب أن تضع في اعتبارك المخاطر الأخرى التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بمرض متوسط أو حاد في الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أُصبت سابقًا بمرض في الكبد، بما في ذلك إلتهاب الكبد الوبائي B أو C (إذا كنت مصابًا بعدوى إلتهاب الكبد الوبائي B، فلا تتوقف عن تناول دوڤاتو بدون استشارة طبيبك، إذ قد يعاودك إلتهاب الكبد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلة في الكلى.</p><p dir="RTL">&not;<strong> استشر طبيبك قبل استخدام </strong><strong>دوڤاتو</strong> إذا كان أي من الحالات السابقة ينطبق عليك. قد تحتاج إلى إجراء المزيد من الفحوصات، بما في ذلك فحوصات الدم، أثناء تناول الدواء. انظر القسم&nbsp;4 لمزيد من المعلومات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>تفاعلات الحساسية</u></p><p dir="RTL">يحتوي دوڤاتو على دولوتيجراڤير. يمكن أن يتسبب دولوتيجراڤير في حدوث رد فعل حساسية خطير يعرف باسم <em>رد فعل فرط الحساسية</em>. يجب عليك معرفة العلامات والأعراض المهمة التي يجب الحذر منها أثناء تناول دوڤاتو.</p><p dir="RTL">&not; <strong>اقرأ معلومات </strong>&quot;تفاعلات الحساسية&quot; الواردة في القسم 4 من هذه النشرة.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>انتبه للأعراض الخطيرة</u></p><p dir="RTL">يصاب بعض الأشخاص الذين يتناولون أدويةً لعلاج &rlm;‫عدوى فيروس نقص المناعة البشرية بحالات أخرى يمكن أن تكون خطيرة. ويشمل ذلك ما يلي:<!--[if supportFields]><span
dir=LTR style='mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
VAULT_ND_e3f75575-3eb8-4918-bf7e-34069bb91e95 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span dir=LTR
style='mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB'><span
style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&middot;&nbsp;&nbsp; أعراض العدوى والإلتهاب</p><p dir="RTL">&middot;&nbsp;&nbsp; تيبس وألم في المفاصل ومشكلات في العظام.</p><p dir="RTL">يجب عليك معرفة العلامات والأعراض المهمة التي يجب الحذر منها أثناء تناول دوڤاتو.<!--[if supportFields]><span
lang=AR-SA style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'><span dir=RTL></span><span dir=RTL></span>
</span><span dir=LTR style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'>VAULT_ND_bddf05de-4fd9-435b-93a2-27bdbe183c32
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&not; <strong>اقرأ معلومات &quot;الآثار الجانبية الأخرى المحتملة&quot; الواردة في القسم 4</strong> من هذه النشرة.<!--[if supportFields]><span
lang=AR-SA style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'><span dir=RTL></span><span dir=RTL></span>
</span><span dir=LTR style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'>VAULT_ND_3ea70f8d-83a5-4f78-9a87-3b15012877db
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يُستخدم هذا الدواء للأطفال الذين تقل أعمارهم عن 12&nbsp;عامًا، ولا للمراهقين الذين يقل وزنهم عن 40 كيلوجرام ، حيث لم تتم دراسته على هذه الفئة من المرضى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى و</strong><strong>دوڤاتو</strong></p><p dir="RTL">أخبر طبيبك إذا كنت تتناول أي أدوية أخرى أو تناولت أي أدوية أخرى مؤخرًا أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتناول دواء دوڤاتو مع الدواء التالي:</p><p dir="RTL">&middot;&nbsp;&nbsp; فامبريدين (المعروف أيضًا بدالفامبريدين) والمستخدم في علاج <strong>مرض التصلب المتعدد</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تؤثر بعض الأدوية على آلية عمل دوڤاتو أو يمكن أن تزيد من احتمال التعرّض للآثار الجانبية. يمكن أن يؤثر دوڤاتو على آلية عمل بعض الأدوية الأخرى.</p><p dir="RTL"><strong>يجب إبلاغ طبيبك </strong>في حالة تناول أي من الأدوية الواردة في القائمة التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميتفورمين لعلاج <strong>السكري</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المعروفة باسم <strong>مضادات الحموضة</strong> لعلاج <strong>عسر الهضم</strong> و<strong>الحموضة المعوية. لا تأخذ أي مضاد للحموضة </strong>خلال الست ساعات التي تسبق تناول دوڤاتو، أو في غضون ساعتين على الأقل من تناوله (انظر أيضًا القسم&nbsp;3، &quot;كيفية تناول دوڤاتو&quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكملات أو المكملات متعددة الفيتامينات المحتوية على الكالسيوم أو الحديد أو المغنيسيوم.<strong> في حال تناول دوڤاتو مع الطعام، </strong>يُمكنك تناول المكملات أو المكملات متعددة الفيتامينات المحتوية على الكالسيوم أو الحديد أو المغنيسيوم في نفس وقت تناول دوڤاتو.<strong> إذا كنت لا تتناول دوڤاتو مع الطعام، فلا تتناول أي مكمل غذائي أو مكمل متعدد الفيتامينات يحتوي على الكالسيوم أو الحديد أو المغنيسيوم </strong>خلال الساعات الست التي تسبق تناول دوڤاتو أو بعد ساعتين على الأقل من تناوله (انظر أيضًا القسم&nbsp;3، &quot;كيفية تناول دوڤاتو&quot;)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمتريسيتابين أو إتراڤيرين أو إيفاڤيرينز أو نيڤيرابين أو تبراناڤير/ريتوناڤير لعلاج <strong>عدوى نقص المناعة البشرية</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية (السائلة عادةً) التي تحتوي على السوربيتول أو غيره من الكحوليات السكرية (مثل زيليتول أو مانيتول أو لاكتيتول أو مالتيتول)، إذا كان تناولها يتم بشكل منتظم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كلادريبين لعلاج <strong>سرطان الدم</strong> أو <strong>التصلب المتعدد</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين لعلاج السل وغيره من أمراض <strong>العدوى البكتيرية</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينيتوين وفينوباربيتال لعلاج <strong>الصرع</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أوكسكاربازيبين وكاربامازيبين لعلاج <strong>الصرع</strong> أو <strong>الاضطراب ثنائي القطب</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>نبتة سانت جونز </strong>(<em>العرن المثقوب</em>)، وهو علاج عشبي لعلاج <strong>الاكتئاب</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &not; <strong>ينبغي إخبار طبيبك أو الصيدلي</strong> إذا كنت تتناول أيًا من هذه الأدوية. قد يقرر طبيبك تعديل الجرعة أو حاجتك إلى إجراء المزيد من الفحوصات.</p><p dir="RTL"><strong>&nbsp;</strong></p><p>&nbsp;</p><p dir="RTL"><strong>الحمل</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span style='mso-element:
field-begin'></span> </span></b><b><span dir=LTR style='font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:
EN-GB'>DOCVARIABLE</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span dir=RTL></span><span
dir=RTL></span> </span></b><b><span dir=LTR style='font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:
EN-GB'>VAULT_ND_72c92954-6ec0-455d-9968-cf777a298d75 \* MERGEFORMAT</span></b><span
dir=RTL></span><span dir=RTL></span><b><span style='font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:
EN-GB'><span dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span
style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p dir="RTL">إذا &rlm;‫كنتِ حاملاً أو تظنين أنكِ حامل أو إذا كنتِ تخططين للإنجاب:<!--[if supportFields]><span
dir=LTR style='mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
VAULT_ND_af453316-a3f3-47a4-9b52-6b9352fc88e3 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
dir=LTR style='mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:
EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>&nbsp;</strong>&not;<strong>تحدث</strong><strong>ي</strong><strong> </strong><strong>مع الطبيب المعالج، </strong>حول المخاطر والفوائد عند تناول دوڤاتو.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبري طبيبك على الفور في حالة حدوث حمل أو كنتِ تنوين الإنجاب. وسيراجع معكِ طبيبكِ علاجك. لا تتوقفي عن تناول دوڤاتو دون استشارة طبيبكِ، لأن هذا قد يضر بكِ وبالجنين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الرضاعة الطبيعية</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span style='mso-element:
field-begin'></span> </span></b><b><span dir=LTR style='font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:
EN-GB'>DOCVARIABLE</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span dir=RTL></span><span
dir=RTL></span> </span></b><b><span dir=LTR style='font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:
EN-GB'>VAULT_ND_fa8ad29b-d1a3-4436-bd65-c7c2a842ad2b \* MERGEFORMAT</span></b><span
dir=RTL></span><span dir=RTL></span><b><span style='font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-ansi-language:
EN-GB'><span dir=RTL></span><span dir=RTL></span> <span lang=AR-SA><span
style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi;mso-ansi-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p dir="RTL"><strong>لا يوصى بالرضاعة الطبيعية </strong><strong>للأمهات المصابات بفيروس نقص المناعة البشرية ،</strong> لأن عدوى فيروس نقص المناعة البشرية يمكنها الانتقال إلى الطفل عبر حليب الأم.<!--[if supportFields]><span lang=AR-SA
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span> </span><span
dir=LTR style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'><span dir=RTL></span><span dir=RTL></span>
</span><span dir=LTR style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'>VAULT_ND_7717eb0f-9c0e-4e60-a2a9-e66a25603e72
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يمكن أيضًا أن تنتقل كمية بسيطة من مكونات دوڤاتو إلى الطفل عبر حليب الأم.<!--[if supportFields]><span
lang=AR-SA style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'><span dir=RTL></span><span dir=RTL></span>
</span><span dir=LTR style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'>VAULT_ND_38892a36-1104-4a1c-8d56-dbf4a3d5d178
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">إذا كنتِ ترضعين طفلكِ رضاعة طبيعية أو تفكرين في الرضاعة الطبيعية ،<strong> ناقشي ذلك مع طبيبكِ فى أقرب فرصة.</strong><!--[if supportFields]><b><span lang=AR-SA
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-hansi-font-family:Symbol;mso-ansi-language:EN-GB'><span style='mso-element:
field-begin'></span> </span></b><b><span dir=LTR style='font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-hansi-font-family:Symbol;
mso-ansi-language:EN-GB'>DOCVARIABLE</span></b><span dir=RTL></span><span
dir=RTL></span><b><span style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-hansi-font-family:Symbol;mso-ansi-language:EN-GB'><span
dir=RTL></span><span dir=RTL></span> </span></b><b><span dir=LTR
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-hansi-font-family:Symbol;mso-ansi-language:EN-GB'>VAULT_ND_905da154-14dc-4a36-b6f7-6151e5a5254b
\* MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-hansi-font-family:Symbol;mso-ansi-language:EN-GB'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-SA><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-hansi-font-family:Symbol;mso-ansi-language:EN-GB'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>
</span></b><b><span dir=LTR style='font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB'>DOCVARIABLE</span></b><span
dir=RTL></span><span dir=RTL></span><b><span style='font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB'><span
dir=RTL></span><span dir=RTL></span> </span></b><b><span dir=LTR
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB'>VAULT_ND_245e57df-61f4-4db6-b888-f2cd68d5c108 \*
MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">يمكن أن يصيبك دوڤاتو بالدوار وغيره من الأعراض الجانبية التي تجعلك أقل انتباهًا.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &not; تجنب القيادة أو تشغيل الآلات ما لم تتأكد من عدم تأثرك.<!--[if supportFields]><span lang=AR-SA style='font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB'><span style='mso-element:field-begin'></span> </span><span dir=LTR
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB'><span dir=RTL></span><span dir=RTL></span> </span><span
dir=LTR style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'>VAULT_ND_cd1b7471-fa86-4142-83a0-66e4e8203c39
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p><strong>دوفاتو يحتوي على الصوديوم</strong><br />يحتوي هذا الدواء على أقل من 1 مللي مول صوديوم (23 مللي جرام) لكل قرص، بمعنى أنه في الأساس يُعد &#39;خاليًا من الصوديوم</p><p dir="RTL"><!--[if supportFields]><span
lang=AR-SA style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL"><!--[if supportFields]><span
lang=AR-SA style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL"><!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب الإلتزام بدقة بتعليمات الطبيب بشأن طريقة تناول هذا الدواء. راجع طبيبك أو الصيدلي في حالة عدم التأكد من ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp; الجرعة الموصى بها من دوڤاتو هي<strong> قرص واحد في اليوم.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">ابتلع القرص مع بعض السوائل. يمكن تناول دوڤاتو مع الطعام أو بدونه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستخدام لدى المراهقين</strong></p><p dir="RTL">يمكن للمراهقين الذين تتراوح أعمارهم بين 12 و17 عامًا ويكون وزنهم 40 كجم على الأقل أخذ جرعة البالغين، وهي قرص واحد مرة واحدة في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مضادات الحموضة</strong></p><p dir="RTL">يمكن أن توقف مضادات الحموضة، التي تُستخدم لعلاج عسر الهضم والحموضة المعوية، امتصاص دوڤاتو في الجسم وتقلل من فعاليته.</p><p dir="RTL">لا تتناول دواءً مضادًا للحموضة خلال الست ساعات التي تسبق تناول دوڤاتو وخلال ساعتين على الأقل من تناوله. يمكنك تناول الأدوية الأخرى التي تقلل الحموضة، مثل الرانيتيدين والأوميبرازول في نفس الوقت الذي تتناول فيه دوڤاتو.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &not; استشر طبيبك للحصول على المشورة بشأن تناول الأدوية التي تقلل الحموضة مع دوڤاتو.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المكملات أو المكملات متعددة الفيتامينات المحتوية على الكالسيوم أو الحديد أو المغنيسيوم</strong></p><p dir="RTL">يمكن أن توقف المكملات أو المكملات متعددة الفيتامينات المحتوية على الكالسيوم أو الحديد أو المغنيسيوم امتصاص دوڤاتو في الجسم وتقلل من فاعليته.</p><p dir="RTL">في حال تناول دوڤاتو مع الطعام، يُمكنك تناول المكملات أو المكملات متعددة الفيتامينات المحتوية على الكالسيوم أو الحديد أو المغنيسيوم في نفس وقت تناول دوڤاتو. إذا كنت لا تتناول دوڤاتو مع الطعام، لا تتناول أي مكمل غذائي أو مكمل متعدد الفيتامينات يحتوي على الكالسيوم أو الحديد أو المغنيسيوم خلال الساعات الست التي تسبق تناول دوڤاتو أو بعد ساعتين على الأقل من تناوله.</p><p dir="RTL">&not; استشر طبيبك طلبًا للمشورة الإضافية بشأن تناول المكملات أو المكملات متعددة الفيتامينات المحتوية على الكالسيوم أو الحديد أو المغنيسيوم مع دوڤاتو.</p><p>&nbsp;</p><p dir="RTL"><strong>في حالة تناول جرعة زائدة من دوڤاتو عما ينبغي تناوله</strong><!--[if supportFields]><b><span lang=AR-SA
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span> </span></b><b><span
dir=LTR style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'>DOCVARIABLE</span></b><span dir=RTL></span><span
dir=RTL></span><b><span style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'><span dir=RTL></span><span dir=RTL></span>
</span></b><b><span dir=LTR style='font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB'>VAULT_ND_8ff3b686-711f-467b-a742-008ea300ff0f
\* MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">عند تناول جرعة زائدة من أقراص دوڤاتو، <strong>اتصل بطبيبك أو الصيدلي طلبًا للمشورة.</strong> ويُفضل أن تريهم عبوة دوڤاتو إن أمكن.<!--[if supportFields]><span lang=AR-SA style='font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB'><span style='mso-element:field-begin'></span> </span><span dir=LTR
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB'><span dir=RTL></span><span dir=RTL></span> </span><span
dir=LTR style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'>VAULT_ND_8a760f71-7692-4354-a6eb-3f167dfcc966
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL"><strong>في حالة نسيان تناول دوڤاتو</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>
</span></b><b><span dir=LTR style='font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB'>DOCVARIABLE</span></b><span
dir=RTL></span><span dir=RTL></span><b><span style='font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB'><span
dir=RTL></span><span dir=RTL></span> </span></b><b><span dir=LTR
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB'>VAULT_ND_2cc62054-29aa-4baa-8dec-91dcbb7e2c49 \*
MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">إذا فاتتك جرعة، فتناولها فور تذكرها. لكن إذا كان موعد الجرعة التالية يحل خلال 4 ساعات، فاقتصر على تناول الجرعة التالية في موعدها المحدد. ثم أكمل العلاج كما في السابق.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &not;<strong>لا تتناول جرعة مضاعفة</strong> لتعويض الجرعة المنسية.</p><p dir="RTL"><strong>لا تتوقف عن تناول دوڤاتو دون استشارة طبيبك</strong><!--[if supportFields]><b><span lang=AR-SA style='font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB'><span style='mso-element:field-begin'></span> </span></b><b><span
dir=LTR style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'>DOCVARIABLE</span></b><span dir=RTL></span><span
dir=RTL></span><b><span style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'><span dir=RTL></span><span dir=RTL></span>
</span></b><b><span dir=LTR style='font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB'>VAULT_ND_b53262ad-2a77-400c-b4d1-363d9ebbfc38
\* MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">تناول دوڤاتو للمدة التي أوصى بها طبيبك. ويجب عدم وقف الدواء إلا إذا أخبرك طبيبك بذلك. يمكن أن يؤثر التوقف عن تناول دوڤاتو على صحتك ومدى فاعلية العلاج في المستقبل.</p><p dir="RTL">&nbsp;</p><p>إذا كانت لديك أي أسئلة أخرى حول استعمال هذا الدواء، يمكنك سؤال طبيبك أو الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يمكن أن يسبب هذا الدواء آثارًا جانبية مثل جميع الأدوية، إلا أنها لا تصيب الجميع، <strong>لذا من المهم جدًا استشارة طبيبك بشأن حدوث أي تغيرات في صحتك</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تفاعلات الحساسية</strong></p><p dir="RTL">يحتوي دوڤاتو على دولوتيجراڤير. يمكن أن يتسبب دولوتيجراڤير في حدوث رد فعل حساسية خطير يعرف باسم <em>رد فعل فرط الحساسية</em>. هذا رد فعل غير شائع لدى المرضى الذين يتناولون دولوتيجراڤير (قد يؤثر على ما يصل إلى مريض واحد من بين 100 مريض). عند ظهور أي من الأعراض التالية عليك:</p><p dir="RTL">&middot;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&middot;&nbsp;&nbsp; ارتفاع درجة الحرارة (<em>الحمى</em>)</p><p dir="RTL">&middot;&nbsp;&nbsp; فقدان الطاقة (<em>التعب</em>)</p><p dir="RTL">&middot;&nbsp;&nbsp; حدوث تورم في بعض الأحيان للوجه والفم (<em>وذمة وعائية</em>) مما ينتج عنه صعوبة في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp; ألم في العضلات أو المفاصل</p><p dir="RTL"><strong>&not;</strong><strong> </strong><strong>استشر طبيبًا على الفور. </strong>قد يقرر طبيبك إجراء اختبارات لفحص حالة كبدك أو كليتيك أو دمك، وقد يطلب منك التوقف عن تناول دوڤاتو.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الشائعة جدًا</strong></p><p dir="RTL">يمكن أن تصيب تلك الآثار <strong>أكثر &rlm;</strong>‫<strong>من مريض واحد من بين 10</strong> مرضى:</p><p dir="RTL">&middot;&nbsp;&nbsp; صداع</p><p dir="RTL">&middot;&nbsp;&nbsp; إسهال</p><p dir="RTL">&middot;&nbsp;&nbsp; شعور بالتوعك (<em>غثيان</em>)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الشائعة</strong></p><p dir="RTL">قد تصيب ما يصل إلى <strong>مريض واحد من بين 10</strong> مرضى:</p><p dir="RTL">&middot;&nbsp;&nbsp; اكتئاب (شعور بالحزن الشديد وعدم الجدارة)</p><p dir="RTL">&middot;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&middot;&nbsp;&nbsp; حكة (<em>جلدية</em>)</p><p dir="RTL">&middot;&nbsp;&nbsp; إعياء (<em>قيء</em>)</p><p dir="RTL">&middot;&nbsp;&nbsp; ألم أو عدم ارتياح في المعدة (<em>البطن</em>)</p><p dir="RTL">&middot;&nbsp;&nbsp; زيادة الوزن</p><p dir="RTL">&middot;&nbsp;&nbsp; ريح (<em>انتفاخ بسبب الغازات</em>)</p><p dir="RTL">&middot;&nbsp;&nbsp; دوار</p><p dir="RTL">&middot;&nbsp;&nbsp; الشعور بالنعاس</p><p dir="RTL">&middot;&nbsp;&nbsp; صعوبة النوم (<em>الأرق</em>)</p><p dir="RTL">&middot;&nbsp;&nbsp; أحلام مزعجة</p><p dir="RTL">&middot;&nbsp;&nbsp; فقدان الطاقة (<em>التعب</em>)</p><p dir="RTL">&middot;&nbsp;&nbsp; تساقط الشعر</p><p dir="RTL">&middot;&nbsp;&nbsp; القلق</p><p dir="RTL">&middot;&nbsp;&nbsp; ألم في المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp; ألم في العضلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">من بين الآثار الجانبية الشائعة التي تظهرها اختبارات الدم:</p><p dir="RTL">&middot;&nbsp;&nbsp; زيادة في مستوى إنزيمات الكبد (<em>ناقلات الأمين</em>)</p><p dir="RTL">&middot;&nbsp;&nbsp; زيادة في مستوى الإنزيمات التي يتم إنتاجها في العضلات (<em>فسفوكيناز الكرياتين</em>).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة</strong></p><p dir="RTL">قد تصيب <strong>ما يصل إلى مريض واحد من بين 100</strong> مريض:</p><p dir="RTL">&middot;&nbsp;&nbsp; إلتهاب الكبد (<em>إلتهاب الكبد الوبائي</em>)</p><p dir="RTL">&middot;&nbsp;&nbsp; محاولة الانتحار (تحديدًا لدى المرضى الذين سبق أن عانوا من الاكتئاب أو من مشكلات نفسية)</p><p dir="RTL">&middot;&nbsp;&nbsp; أفكار انتحارية (تحديدًا لدى المرضى الذين سبق أن عانوا من الاكتئاب أو من مشكلات نفسية).</p><p dir="RTL">&middot;&nbsp;&nbsp; نوبة الهلع (الخوف).</p><p dir="RTL">&nbsp;</p><p dir="RTL">من بين الآثار الجانبية غير الشائعة التي تظهرها اختبارات الدم:</p><p dir="RTL">&middot;&nbsp;&nbsp; انخفاض في عدد الخلايا المشاركة في تجلط الدم (<em>قلة الصفيحات</em>).</p><p dir="RTL">&middot;&nbsp;&nbsp; انخفاض عدد خلايا الدم الحمراء (<em>الأنيميا</em>) أو انخفاض عدد خلايا الدم البيضاء (<em>نقص العدلات</em>).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية النادرة</strong></p><p dir="RTL">قد تصيب <strong>ما يصل إلى مريض واحد من بين 1000</strong> مريض:</p><p dir="RTL">&middot;&nbsp;&nbsp; فشل كبدي (قد تشمل العلامات اصفرار الجلد وبياض العينين أو البول الداكن بشكل غير عادي)</p><p dir="RTL">&middot;&nbsp;&nbsp; حدوث تورم في بعض الأحيان للوجه والفم (<em>وذمة وعائية</em>) مما ينتج عنه صعوبة في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp; حدوث إلتهاب في البنكرياس (<em>إلتهاب البنكرياس</em>)</p><p dir="RTL">&middot;&nbsp;&nbsp; تمزق في الأنسجة العضلية.</p><p dir="RTL">&middot;&nbsp;&nbsp; الانتحار (خاصة فى المرضى الذين كان لديهم اكتئاب او أمراض نفسية سابقا)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&not;</strong><strong>تحدث مع طبيبك على الفور </strong>اذا كنت تعانى من أي أمراض نفسية (انظر أيضا الأمراض النفسية الأخرى أعلاه.( &nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية النادرة التي قد تظهر في اختبارات الدم هي:</p><p dir="RTL">&middot;&nbsp;&nbsp; زيادة في مستوى البيليروبين (تحليل وظائف الكبد)</p><p dir="RTL">&middot;&nbsp;&nbsp; زيادة في إنزيم يُعرف باسم <em>الأميلاز</em>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية النادرة جدًا</strong></p><p dir="RTL">قد تصيب <strong>ما يصل إلى مريض واحد من بين 10,000</strong> مريض:</p><p dir="RTL">&middot;&nbsp;&nbsp; حُماض لاكتيكي (مستويات زائدة من حمض اللاكتيك في الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp; التنميل، الشعور بالوخز في الجلد (كأنه وخز بالإبر والدبابيس)</p><p dir="RTL">&middot;&nbsp;&nbsp; الإحساس بضعف في الأطراف.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من بين الآثار الجانبية شديدة الندرة التي تظهرها اختبارات الدم:</p><p dir="RTL">&middot;&nbsp;&nbsp; فشل النخاع العظمي في إنتاج خلايا دم حمراء جديدة <em>(عدم تنسج كريات دم حمراء نقية)</em>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية المحتملة الأخرى</strong></p><p dir="RTL">قد يتعرض المرضى الذين يتناولون علاجًا مركبًا لفيروس نقص المناعة البشرية إلى آثار جانبية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض العدوى والإلتهاب </strong></p><p dir="RTL">يعاني المرضى المصابون بحالة متقدمة من عدوى الإيدز أو فيروس نقص المناعة البشرية من أجهزة مناعية ضعيفة، ويصبحون أكثر عرضة للإصابة بعدوى خطيرة (عدوى انتهازية). قد لا تعلن هذه العدوى عن نفسها ولا تُظهر أي أعراض، وبالتالي لن يكتشفها الجهاز المناعي الضعيف قبل بدء العلاج. بعد بدء العلاج، يصبح الجهاز المناعي أكثر قوة، ويهاجم العدوى، مما يؤدي إلى ظهور أعراض العدوى أو الإلتهاب. عادة ما تشمل الأعراض الحمى، بالإضافة إلى بعض الأعراض التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp; صداع</p><p dir="RTL">&middot;&nbsp;&nbsp; ألم في المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp; صعوبة في التنفس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالات نادرة، بمجرد أن يصبح الجهاز المناعي أكثر قوة، قد يهاجم أنسجة الجسم السليمة (<em>اضطرابات المناعة الذاتية</em>). وربما تظهر أعراض اضطرابات المناعة الذاتية بعد أشهر من تناول الدواء لعلاج عدوى فيروس نقص المناعة البشرية. قد تشمل الأعراض:</p><p dir="RTL">&middot;&nbsp;&nbsp; خفقان القلب (ضربات قلب سريعة أو غير منتظمة) أو الارتجاف</p><p dir="RTL">&middot;&nbsp;&nbsp; فرط النشاط (التململ والحركة الزائدة)</p><p dir="RTL">&middot;&nbsp;&nbsp; ضعف يبدأ في اليدين والقدمين وينتقل لأعلى البدن.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا أصابك أي من أعراض العدوى،</strong> أو لاحظت أيًا من الأعراض المذكورة أعلاه:</p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>&not;</strong><strong> </strong><strong>يجب إبلاغ طبيبك على الفور</strong>. ولا تتناول أي أدوية أخرى لعلاج العدوى دون استشارة طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تيبس وألم في المفاصل ومشكلات في العظام</strong></p><p dir="RTL">يصاب بعض الأشخاص الذين يتناولون العلاج المركب لفيروس نقص المناعة البشرية بحالة يُطلَق عليها &nbsp;<em>النخر العظمي</em>. في هذه الحالة، تتلف أجزاء من أنسجة العظام بشكل دائم بسبب انخفاض تدفق الدم إلى العظام. تزداد احتمالية الإصابة بهذه الحالة لدى المرضى:</p><p dir="RTL">&middot;&nbsp;&nbsp; إذا كانوا يتناولون علاجًا مركبًا لفترة طويلة من الوقت</p><p dir="RTL">&middot;&nbsp;&nbsp; إذا كانوا يتناولون الأدوية المضادة للإلتهابات التي يُطلق عليها الكورتيكوستيرويدات</p><p dir="RTL">&middot;&nbsp;&nbsp; إذا كانوا يتناولون مشروبات كحولية</p><p dir="RTL">&middot;&nbsp;&nbsp; إذا كانوا يعانون من ضعف شديد في جهازهم المناعي</p><p dir="RTL">&middot;&nbsp;&nbsp; إذا كانوا يعانون من زيادة الوزن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تشمل علامات النخر العظمي:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp; تيبس المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp; أوجاع وآلام في المفاصل (خاصةً في الورك أو الركبة أو الكتف)</p><p dir="RTL">&middot;&nbsp;&nbsp; صعوبة الحركة.</p><p dir="RTL">عند ملاحظة أي من هذه الأعراض:</p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>&not;</strong><strong> </strong><strong>أخبر طبيبك.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تأثيرات الوزن، ونسبة الدهون في الدم، ومستوى الجلوكوز في الدم</strong></p><p dir="RTL">أثناء علاج فيروس نقص المناعة البشرية، قد يكون هناك زيادة في الوزن ومستويات الدهون والجلوكوز في الدم. ويرتبط هذا جزئيًا باستعادة الصحة ونمط الحياة، و أحيانًا بأدوية فيروس نقص المناعة البشرية نفسها. سيطلب منك الطبيب المعالج عمل التحاليل لرصد هذه التغييرات.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>
</span></b><b><span dir=LTR style='font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB'>DOCVARIABLE</span></b><span
dir=RTL></span><span dir=RTL></span><b><span style='font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB'><span
dir=RTL></span><span dir=RTL></span> </span></b><b><span dir=LTR
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB'>VAULT_ND_6895612c-8fb4-46c5-b80b-c18d5dc80bc4 \*
MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-SA style='font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">في حالة ظهور أي أعراض جانبية، أبلغ طبيبك أو الصيدلي. وهذا يتضمن أي آثار جانبية محتملة غير واردة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب حفظ الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية وعلى الزجاجة بعد كلمة &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر المذكور.</p><p dir="RTL">يحفظ دوڤاتو في درجة حرارة لا تزيد عن 30 درجة مئوية</p><p dir="RTL">&rlm;‫لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. استشر الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستعملها. فهذه الإجراءات من شأنها أن تحافظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مكونات دوڤاتو </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; المادتان الفعَّالتان هما دولوتيجراڤير ولاميڤودين. يحتوي كل قرص على صوديوم دولوتيجراڤير يعادل 50&nbsp;ملجم من دولوتيجراڤير و300&nbsp;ملجم من لاميڤودين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; المكوّنات الأخرى هي سليلوز دقيق التبلور وجلايكولات نشاء الصوديوم وسترات الماغنيسيوم ومانيتول (E421) وبوفيدون (K29/32) وفومارات ستيريل الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص دوڤاتو المكسوة بغلاف غشائي هي أقراص بيضاء ومحدبة الوجهين وبيضاوية الشكل ومطبوع على أحد جانبي القرص</p><p dir="RTL">&quot;SV 137&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تأتي الأقراص المغلَّفة في عبوة مغلقة بأغطية مقاومة لعبث الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي كل عبوة على 30 قرصًا مكسو بغلاف غشائي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا تتوفر جميع أحجام العبوات في بلدك.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>تصنيع:</strong></p><p dir="RTL">جلاكسو سميث كلاين إل إل سي، زبليون، كارولينا الشمالية، الولايات المتحدة الأمريكية</p><p dir="RTL"><strong>تعبئة:</strong></p><p dir="RTL">جلاكسو ويلكم أس. أيه.*، أرندا،&nbsp; اسبانيا</p><p dir="RTL"><strong>تسويق:</strong></p><p dir="RTL">جلاكسو العربية السعودية المحدودة*، جدة، ، المملكة العربية السعودية</p><p dir="RTL">*عضو في مجموعة شركات جلاكسو سميث كلاين</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            رقم الإصدار: EMEAv20
تاريخ الإصدار:31 اكتوبر 2024 


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dovato 50 mg/300 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains dolutegravir sodium equivalent to 50 mg dolutegravir and 300 mg lamivudine.

For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet).

Oval, biconvex, white, film coated tablet, approximately 18.5 x 9.5 mm, debossed with “SV 137” on one face.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dovato is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12&nbsp;years of age weighing at least 40&nbsp;kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dovato should be prescribed by physicians experienced in the management of HIV infection.</p><p><strong><em>&nbsp;</em></strong></p><p><u>Posology</u></p><p><strong>Adults and adolescents (above 12&nbsp;years of age weighing at least 40</strong><strong>&nbsp;kg).</strong></p><p><em>&nbsp;</em></p><p>The recommended dose of Dovato in adults and adolescents is one 50&nbsp;mg/300&nbsp;mg tablet once daily.</p><p>&nbsp;</p><p><strong>Dose adjustments</strong></p><p>A separate preparation of dolutegravir is available where a dose adjustment is indicated due to drug-drug interactions (e.g. rifampicin, carbamazepine, oxcarbazepine, phenytoin, phenobarbital, St. John&rsquo;s wort, etravirine (without boosted protease inhibitors), efavirenz, nevirapine, or tipranavir/ritonavir, see sections 4.4 and 4.5). In these cases, the physician should refer to the individual product information for dolutegravir.</p><p>&nbsp;</p><p><strong>Missed doses</strong></p><p>If the patient misses a dose of Dovato, the patient should take Dovato as soon as possible, providing the next dose is not due within 4&nbsp;hours. If the next dose is due within 4&nbsp;hours, the patient should not take the missed dose and simply resume the usual dosing schedule.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Elderly</strong></p><p>There are limited data available on the use of Dovato in patients aged 65&nbsp;years and over. No dose adjustment is necessary (see section 5.2).</p><p><em>&nbsp;</em></p><p><strong>Renal impairment</strong></p><p>Dovato is not recommended for use in patients with a creatinine clearance &lt; 30&nbsp;mL/min (see section 5.2). No dose adjustment is required in patients with mild or moderate renal impairment. However, the lamivudine exposure is significantly increased in patients with a creatinine clearance &lt; 50 mL/min (see section 4.4).</p><p><em>&nbsp;</em></p><p><strong>Hepatic impairment</strong></p><p>No dosage adjustment is required in patients with mild or moderate hepatic impairment (Child-Pugh grade A or B). No data are available in patients with severe hepatic impairment (Child-Pugh grade C); therefore Dovato should be used with caution in these patients (see section 5.2).</p><p>&nbsp;</p><p><strong>Paediatric population</strong></p><p>The safety and efficacy of Dovato in children aged less than 12&nbsp;years and in adolescents weighing less than 40&nbsp;kg have not been established. No data are available.</p><p>&nbsp;</p><p><strong>Method of administration</strong></p><p>Oral use.</p><p>Dovato can be taken with or without food (see section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.

Co-administration with medicinal products with narrow therapeutic windows, that are substrates of organic cation transporter (OCT) 2, including but not limited to fampridine (also known as dalfampridine; see section 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Hypersensitivity reactions</strong></p><p>Hypersensitivity reactions have been reported with dolutegravir, and were characterized by rash, constitutional findings, and sometimes, organ dysfunction, including severe liver reactions. Dovato and other suspect medicinal products should be discontinued immediately if signs or symptoms of hypersensitivity reactions develop (including, but not limited to, severe rash or rash accompanied by raised liver enzymes, fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial oedema, eosinophilia, angioedema). Clinical status including liver aminotransferases and bilirubin should be monitored. Delay in stopping treatment with Dovato or other suspect active substances after the onset of hypersensitivity may result in a life-threatening allergic reaction.</p><p><u>&nbsp;</u></p><p><strong>Weight and metabolic parameters</strong></p><p>An increase in weight and in levels of blood lipids and glucose may occur during antiretroviral therapy. Such changes may in part be linked to disease control and lifestyle. For lipids and weight, there is in some cases evidence for a treatment effect For monitoring of blood lipids and glucose reference is made to established HIV treatment guidelines. Lipid disorders should be managed as clinically appropriate.</p><p><strong>Liver disease</strong></p><p>Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk of severe and potentially fatal hepatic adverse reactions. In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant product information for these medicinal products.</p><p>&nbsp;</p><p>Dovato includes lamivudine, which is active against hepatitis B. Dolutegravir lacks such activity. Lamivudine monotherapy is generally not considered an adequate treatment for hepatitis B since the risk for hepatitis B resistance development is high. If Dovato is used in patients co-infected with hepatitis B an additional antiviral is therefore generally needed. Reference should be made to treatment guidelines.</p><p>&nbsp;</p><p>If Dovato is discontinued in patients co-infected with hepatitis B virus, periodic monitoring of both liver function tests and markers of HBV replication is recommended, as withdrawal of lamivudine may result in an acute exacerbation of hepatitis.</p><p>&nbsp;</p><p>Patients with pre-existing liver dysfunction, including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy, and should be monitored according to standard practice. If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment must be considered.</p><p>&nbsp;</p><p><strong>Immune reactivation syndrome</strong></p><p>In HIV-infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms. Typically, such reactions have been observed within the first few weeks or months of initiation of CART. Relevant examples are <em>Cytomegalovirus retinitis</em>, generalised and/or focal mycobacterial infections, and <em>Pneumocystis jirovecii</em> pneumonia (often referred to as PCP). Any inflammatory symptoms should be evaluated, and treatment instituted when necessary. Autoimmune disorders (such as Graves&rsquo; disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment.</p><p>&nbsp;</p><p>Liver chemistry elevations consistent with immune reconstitution syndrome were observed in some hepatitis B and/or C co-infected patients at the start of dolutegravir therapy. Monitoring of liver chemistries is recommended in patients with hepatitis B and/or C co-infection. (See &lsquo;Liver disease&rsquo; earlier in this section and also see section 4.8).</p><p>&nbsp;</p><p><strong>Mitochondrial dysfunction following exposure <em>in utero</em></strong></p><p>Nucleoside and nucleotide analogues may impact mitochondrial function to a variable degree, which is most pronounced with stavudine, didanosine and zidovudine. There have been reports of mitochondrial dysfunction in HIV-negative infants exposed <em>in utero</em> and/or post-natally to nucleoside analogues, these have predominantly concerned treatment with regimens containing zidovudine. The main adverse reactions reported are haematological disorders (anaemia, neutropenia), and metabolic disorders (hyperlactatemia, hyperlipasemia). These reactions have often been transitory. Some late-onset neurological disorders have been reported rarely (hypertonia, convulsion, abnormal behaviour). Whether such neurological disorders are transient or permanent is currently unknown. These findings should be considered for any child exposed <em>in utero</em> to nucleoside and nucleotide analogues, who presents with severe clinical findings of unknown aetiology, particularly neurologic findings. These findings do not affect current national recommendations to use antiretroviral therapy in pregnant women to prevent vertical transmission of HIV.</p><p><u>&nbsp;</u></p><p><strong>Osteonecrosis</strong></p><p>Although the aetiology is considered to be multifactorial (including corticosteroid use, biphosphonates, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported in patients with advanced HIV-disease and/or long-term exposure to CART. Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement.</p><p>&nbsp;</p><p><strong>Opportunistic infections</strong></p><p>Patients should be advised that dolutegravir, lamivudine or any other antiretroviral therapy does not cure HIV infection and that they may still develop opportunistic infections and other complications of HIV infection. Therefore, patients should remain under close clinical observation by physicians experienced in the treatment of these associated HIV diseases.</p><p>&nbsp;</p><p><strong>Administration in subjects with moderate renal impairment</strong></p><p>Patients with a creatinine clearance between 30 and 49 mL/min receiving Dovato may experience a 1.6-to 3.3-fold higher lamivudine exposure (AUC) than patients with a creatinine clearance &ge;50 mL/min. There are no safety data from randomized, controlled trials comparing Dovato to the individual components in patients with a creatinine clearance between 30 and 49 mL/min who received dose-adjusted lamivudine. In the original lamivudine registrational trials in combination with zidovudine, higher lamivudine exposures were associated with higher rates of haematologic toxicities (neutropenia and anaemia), although discontinuations due to neutropenia or anaemia each occurred in &lt;1% of subjects. Other lamivudine-related adverse reactions (such as gastro-intestinal and hepatic disorders) may occur.</p><p>&nbsp;</p><p>Patients with a sustained creatinine clearance between 30 and 49 mL/min who receive Dovato should be monitored for lamivudine-related adverse reactions, notably haematologic toxicities. If new or worsening neutropenia or anaemia develop, a dose adjustment of lamivudine, per lamivudine prescribing information, is indicated, which cannot be achieved with Dovato. Dovato should be discontinued and the individual components should be used to construct the treatment regimen.</p><p>&nbsp;</p><p><strong>Drug interactions</strong></p><p>The recommended dose of dolutegravir is 50&nbsp;mg twice daily when co-administered with rifampicin, carbamazepine, oxcarbazepine, phenytoin, phenobarbital, St. John&rsquo;s wort, etravirine (without boosted protease inhibitors), efavirenz, nevirapine, or tipranavir/ritonavir (see section 4.5).</p><p>&nbsp;</p><p>Dovato should not be co-administered with polyvalent cation-containing antacids. Polyvalent cation-containing antacids are recommended to be taken 2&nbsp;hours after or 6&nbsp;hours before Dovato (see section 4.5).</p><p>&nbsp;</p><p>When taken with food, Dovato and supplements or multivitamins containing calcium, iron or magnesium can be taken at the same time. If Dovato is administered under fasting conditions, supplements or multivitamins containing calcium, iron or magnesium are recommended to be taken 2&nbsp;hours after or 6&nbsp;hours before Dovato (see section 4.5).</p><p>&nbsp;</p><p>Dolutegravir increased metformin concentrations. A dose adjustment of metformin should be considered when starting and stopping coadministration of Dovato with metformin, to maintain glycaemic control (see section 4.5). Metformin is eliminated renally and, therefore, it is of importance to monitor renal function when co-treated with Dovato. This combination may increase the risk for lactic acidosis in patients with moderate renal impairment (stage 3a creatinine clearance 45&ndash; 59&nbsp;mL/min) and a cautious approach is recommended. Reduction of the metformin dose should be highly considered.</p><p>The combination of Dovato with cladribine is not recommended (see section 4.5).</p><p>&nbsp;</p><p>Dovato should not be taken with any other medicinal product containing dolutegravir, lamivudine or emtricitabine, except where a dose adjustment of dolutegravir is indicated due to drug-drug interactions (see section 4.5).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No drug interaction studies have been conducted using Dovato. Dovato contains dolutegravir and lamivudine, therefore any interactions identified for these individually are relevant to Dovato. No clinically significant drug interactions are expected between dolutegravir and lamivudine.</p><p>&nbsp;</p><p><strong>Effect of other medicinal products on the pharmacokinetics of dolutegravir and lamivudine</strong></p><p>Dolutegravir is eliminated mainly through metabolism by uridine diphosphate glucuronosyl transferase (UGT) 1A1. Dolutegravir is also a substrate of UGT1A3, UGT1A9, CYP3A4, P-glycoprotein (P-gp), and breast cancer resistance protein<strong><em> </em></strong>(BCRP). Co-administration of Dovato and other medicinal products that inhibit UGT1A1, UGT1A3, UGT1A9, CYP3A4, and/or P-gp may, therefore, increase dolutegravir plasma concentration. Medicinal products that induce those enzymes or transporters may decrease dolutegravir plasma concentration and reduce the therapeutic effect of dolutegravir.</p><p>&nbsp;</p><p>The absorption of dolutegravir is reduced by certain metal cation-containing anti-acid substances and supplements (see Table 1).</p><p>&nbsp;</p><p>Lamivudine is cleared renally. Active renal secretion of lamivudine in the urine is mediated through the OCT 2 and multidrug and toxin extrusion transporters (MATE1 and MATE2-K). Trimethoprim (an inhibitor of these transporters) has been shown to increase lamivudine plasma concentrations, however the resulting increase was not clinically significant (see Table 1). Dolutegravir is an OCT2 and MATE1 inhibitor; however, lamivudine concentrations were similar with or without co‑administration of dolutegravir based on a cross study analysis, indicating that dolutegravir has no relevant effect on lamivudine exposure <em>in vivo</em>. Lamivudine is also substrate of the hepatic uptake transporter OCT1. As hepatic elimination plays a minor role in the clearance of lamivudine, drug interactions due to inhibition of OCT1 are unlikely to be of clinical significance.</p><p>&nbsp;</p><p>Although lamivudine is a substrate of BCRP and P-gp <em>in vitro</em>, given its high absolute bioavailability, (see section 5.2), inhibitors of these efflux transporters are unlikely to result in a clinically relevant impact on lamivudine concentrations.</p><p>&nbsp;</p><p><strong>Effect of dolutegravir and lamivudine on the pharmacokinetics of other medicinal products</strong></p><p><em>In vivo</em>, dolutegravir did not have an effect on midazolam, a CYP3A4 probe. Based on <em>in vivo</em> and/or <em>in vitro</em> data, dolutegravir is not expected to affect the pharmacokinetics of medicinal products that are substrates of any major enzyme or transporter such as CYP3A4, CYP2C9 and P-gp (for more information see section 5.2).</p><p>&nbsp;</p><p><em>In vitro</em>, dolutegravir inhibited the renal transporters OCT2 and MATE1. <em>In vivo</em>, a 10-14% decrease of creatinine clearance (secretory fraction is dependent on OCT2 and MATE1 transport) was observed in patients. <em>In vivo</em>, dolutegravir may increase plasma concentrations of medicinal products in which excretion is dependent upon OCT2 and/or MATE1 (e.g. fampridine [also known as dalfampridine], metformin) (see Table 1 and section 4.3).</p><p>&nbsp;</p><p><em>In vitro</em>, dolutegravir inhibited the renal uptake organic anion transporters (OAT)1 and OAT3. Based on the lack of effect on the <em>in vivo</em> pharmacokinetics of the OAT substrate tenofovir, <em>in vivo</em> inhibition of OAT1 is unlikely. Inhibition of OAT3 has not been studied <em>in vivo</em>. Dolutegravir may increase plasma concentrations of medicinal products in which excretion is dependent upon OAT3.</p><p>&nbsp;</p><p><em>In vitro,</em> lamivudine was an inhibitor of OCT1 and OCT2; the clinical consequences are not known.</p><p>&nbsp;</p><p>Established and theoretical interactions with selected antiretrovirals and non-antiretroviral medicinal products are listed in Table 1.</p><p>&nbsp;</p><p><strong>Interaction table</strong></p><p>Interactions between dolutegravir, lamivudine and co-administered medical products are listed in Table 1 (increase is indicated as &ldquo;&uarr;&rdquo;, decrease as &ldquo;&darr;&rdquo;, no change as &ldquo;&harr;&rdquo;, area under the concentration versus time curve as &ldquo;AUC&rdquo;, maximum observed concentration as &ldquo;C<sub>max</sub>&rdquo;, concentration at end of dosing interval as &ldquo;C&tau;&rdquo;). The table should not be considered exhaustive but is representative of the classes studied.</p><p>&nbsp;</p><p><strong>Table 1:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drug Interactions</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:632px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Medicinal products by therapeutic areas</strong></p></td><td style="vertical-align:top"><p><strong>Interaction geometric mean change (%) </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Recommendations concerning co-administration</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Antiretroviral medicinal products</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Non-nucleoside reverse transcriptase inhibitors</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Etravirine without boosted protease inhibitors / Dolutegravir</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;<br />&nbsp;&nbsp; AUC &macr; 71%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 52%<br />&nbsp;&nbsp; Ct &macr; 88%<br />&nbsp;</p><p>Etravirine &laquo;</p><p>(induction of UGT1A1 and CYP3A enzymes)</p></td><td colspan="2" style="vertical-align:top"><p>Etravirine without boosted protease inhibitors decreased plasma dolutegravir concentration. The recommended dose of dolutegravir is 50&nbsp;mg twice daily for patients taking etravirine without boosted protease inhibitors. As Dovato is a fixed-dose tablet, an additional 50&nbsp;mg tablet of dolutegravir should be administered, approximately 12&nbsp;hours after Dovato for the duration of the etravirine without boosted protease inhibitor co-administration (a separate formulation of dolutegravir is available for this dose adjustment, see section 4.2).</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Lopinavir+ritonavir+etravirine/ Dolutegravir</p></td><td style="vertical-align:top"><p>Dolutegravir &laquo;<br />&nbsp;&nbsp; AUC &shy; 11%<br />&nbsp;&nbsp; C<sub>max</sub> &shy; 7%<br />&nbsp;&nbsp; Ct &shy; 28%</p><p>&nbsp;</p><p>Lopinavir &laquo;<br />Ritonavir &laquo;<br />Etravirine &laquo;</p></td><td colspan="2" style="vertical-align:top"><p>No dose adjustment is necessary.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Darunavir+ritonavir+etravirine/ Dolutegravir</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;<br />&nbsp;&nbsp; AUC &macr; 25%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 12%<br />&nbsp;&nbsp; Ct &macr; 36%</p><p>&nbsp;</p><p>Darunavir &laquo;<br />Ritonavir &laquo;<br />Etravirine &laquo;</p></td><td colspan="2" style="vertical-align:top"><p>No dose adjustment is necessary.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Efavirenz/Dolutegravir</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;<br />&nbsp;&nbsp; AUC &macr; 57%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 39%<br />&nbsp;&nbsp; Ct &macr; 75%<br />&nbsp;</p><p>Efavirenz &laquo; (historical controls)</p><p>(induction of UGT1A1 and CYP3A enzymes)</p></td><td colspan="2" style="vertical-align:top"><p>The recommended dose of dolutegravir is 50&nbsp;mg twice daily when co‑administered with efavirenz. As Dovato is a fixed-dose tablet, an additional 50&nbsp;mg tablet of dolutegravir should be administered, approximately 12&nbsp;hours after Dovato for the duration of the efavirenz co-administration (a separate formulation of dolutegravir is available for this dose adjustment, see section 4.2).</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Nevirapine/Dolutegravir</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;</p><p>(Not studied, a similar reduction in exposure as observed with efavirenz is expected, due to induction)</p></td><td colspan="2" style="vertical-align:top"><p>The recommended dose of dolutegravir is 50&nbsp;mg twice daily when co‑administered with nevirapine. As Dovato is a fixed-dose tablet, an additional 50&nbsp;mg tablet of dolutegravir should be administered, approximately 12&nbsp;hours after Dovato for the duration of the nevirapine co-administration (a separate formulation of dolutegravir is available for this dose adjustment, see section 4.2).</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Rilpivirine/Dolutegravir</p></td><td style="vertical-align:top"><p>Dolutegravir &laquo;</p><p>&nbsp;&nbsp; AUC &shy; 12%</p><p>&nbsp;&nbsp; C<sub>max</sub> &shy; 13%</p><p>&nbsp;&nbsp; C&tau; &shy; 22%</p><p>Rilpivirine &laquo;</p></td><td colspan="2" style="vertical-align:top"><p>No dose adjustment is necessary.</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Nucleoside reverse transcriptase inhibitors (NRTIs)</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Tenofovir disoproxil</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Emtricitabine, didanosine, stavudine, tenofovir alafenamide, zidovudine</p></td><td style="vertical-align:top"><p>Dolutegravir &laquo;</p><p>&nbsp;&nbsp; AUC &shy; 1%</p><p>&nbsp;&nbsp; C<sub>max</sub> &macr; 3%</p><p>&nbsp;&nbsp; C&tau; &macr; 8%</p><p>Tenofovir &laquo;</p><p>&nbsp;</p><p>&nbsp;</p><p>Interaction not studied</p><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>No dose adjustment is necessary when Dovato is combined with tenofovir, didanosine, stavudine or zidovudine.</p><p>&nbsp;</p><p>Dovato is not recommended for use in combination with emtricitabine containing products, since both lamivudine (in Dovato) and emtricitabine are cytidine analogues (i.e. risk for intracellular interactions), see section 4.4.</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Protease inhibitors</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Atazanavir/Dolutegravir</p></td><td style="vertical-align:top"><p>Dolutegravir &shy;<br />&nbsp;&nbsp; AUC &shy; 91%<br />&nbsp;&nbsp; C<sub>max</sub> &shy; 50%<br />&nbsp;&nbsp; Ct &shy; 180%<br />&nbsp;</p><p>Atazanavir &laquo; (historical controls)</p><p>(inhibition of UGT1A1 and CYP3A enzymes)</p></td><td colspan="2" style="vertical-align:top"><p>No dose adjustment is necessary.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Atazanavir+ ritonavir/ Dolutegravir</p></td><td style="vertical-align:top"><p>Dolutegravir &shy;<br />&nbsp;&nbsp; AUC &shy; 62%<br />&nbsp;&nbsp; C<sub>max</sub> &shy; 34%<br />&nbsp;&nbsp; Ct &shy; 121%<br />&nbsp;</p><p>Atazanavir &laquo;<br />Ritonavir &laquo;</p></td><td colspan="2" style="vertical-align:top"><p>No dose adjustment is necessary.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Tipranavir+ritonavir/ Dolutegravir</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;<br />&nbsp;&nbsp; AUC &macr; 59%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 47%<br />&nbsp;&nbsp; Ct &macr; 76%<br />&nbsp;</p><p>Tipranavir &laquo;<br />Ritonavir &laquo;</p><p>(induction of UGT1A1 and CYP3A enzymes)</p></td><td colspan="2" style="vertical-align:top"><p>The recommended dose of<s> </s>dolutegravir is 50&nbsp;mg twice daily when co&nbsp;administered with tipranavir/ritonavir. As Dovato is a fixed-dose tablet, an additional 50&nbsp;mg tablet of dolutegravir should be administered, approximately 12&nbsp;hours after Dovato for the duration of the tipranavir/ritonavir co-administration (a separate formulation of dolutegravir is available for this dose adjustment, see section 4.2).</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Fosamprenavir+ritonavir/ Dolutegravir</p></td><td style="vertical-align:top"><p>Dolutegravir&macr;<br />&nbsp;&nbsp; AUC &macr; 35%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 24%<br />&nbsp;&nbsp; Ct &macr; 49%<br />&nbsp;</p><p>Fosamprenavir&laquo;</p><p>Ritonavir &laquo;</p><p>(induction of UGT1A1 and CYP3A enzymes)</p></td><td colspan="2" style="vertical-align:top"><p>Fosamprenavir/ritonavir decreases dolutegravir concentrations, but based on limited data, did not result in decreased efficacy in Phase III studies. No dose adjustment is necessary.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Lopinavir+ritonavir/ Dolutegravir</p></td><td style="vertical-align:top"><p>Dolutegravir &laquo;<br />&nbsp;&nbsp; AUC &macr; 4%<br />&nbsp;&nbsp; C<sub>max</sub> &laquo; 0%<br />&nbsp;&nbsp; C<sub>24</sub> &macr; 6%</p><p>&nbsp;</p><p>Lopinavir &laquo;<br />Ritonavir &laquo;</p></td><td colspan="2" style="vertical-align:top"><p>No dose adjustment is necessary.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Darunavir+ritonavir/ Dolutegravir</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;<br />&nbsp;&nbsp; AUC &macr; 22%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 11%<br />&nbsp;&nbsp; Ct &macr; 38%</p><p>&nbsp;</p><p>Darunavir &laquo;<br />Ritonavir &laquo;</p><p>(induction of UGT1A1 and CYP3A enzymes)</p></td><td colspan="2" style="vertical-align:top"><p>No dose adjustment is necessary.</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Other antiviral active substances</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Daclatasvir/Dolutegravir</p></td><td style="vertical-align:top"><p>Dolutegravir &laquo;<br />&nbsp;&nbsp; AUC &shy; 33%<br />&nbsp;&nbsp; C<sub>max</sub> &shy; 29%<br />&nbsp;&nbsp; Ct &shy; 45%</p><p>Daclatasvir &laquo;</p></td><td colspan="2" style="vertical-align:top"><p>Daclatasvir did not change dolutegravir plasma concentration to a clinically relevant extent. Dolutegravir did not change daclatasvir plasma concentration. No dose adjustment is necessary.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Ledipasvir/Sofosbuvir/<br />Lamivudine (with abacavir)</p></td><td style="vertical-align:top"><p>Lamivudine &laquo;</p><p>Ledipasvir &laquo;</p><p>Sofosbuvir &laquo;</p></td><td colspan="2" style="vertical-align:top"><p>No dosage adjustment necessary.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Sofosbuvir/ Velpatasvir/Dolutegravir</p></td><td style="vertical-align:top"><p>Dolutegravir &laquo;</p><p>Sofosbuvir &laquo;</p><p>Velpatasvir&laquo;</p></td><td colspan="2" style="vertical-align:top"><p>No dosage adjustment necessary.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Ribavirin</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Clinically significant interaction unlikely.</p></td><td colspan="2" style="vertical-align:top"><p>No dosage adjustment necessary.</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Anti-infective products</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Trimethoprim/sulfamethoxazole</p><p>(Co-trimoxazole)/Lamivudine</p><p>(160&nbsp;mg/800&nbsp;mg once daily for 5&nbsp;days/300&nbsp;mg single dose)</p></td><td style="vertical-align:top"><p>Lamivudine:</p><p>&nbsp;&nbsp; AUC &shy; 43%</p><p>&nbsp;&nbsp; C<sub>max</sub> &shy; 7%</p><p>&nbsp;</p><p>Trimethoprim:</p><p>&nbsp;&nbsp; AUC &laquo;</p><p>&nbsp;</p><p>Sulfamethoxazole:</p><p>&nbsp;&nbsp; AUC &laquo;</p><p>&nbsp;</p><p>(organic cation transporter inhibition)</p></td><td colspan="2" style="vertical-align:top"><p>No dosage adjustment necessary.</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Antimycobacterials</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Rifampicin/Dolutegravir</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;<br />&nbsp;&nbsp; AUC &macr; 54%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 43%<br />&nbsp;&nbsp; Ct &macr; 72%</p><p>(induction of UGT1A1 and CYP3A enzymes)</p></td><td colspan="2" style="vertical-align:top"><p>The recommended dose of dolutegravir is 50&nbsp;mg twice daily when co‑administered with rifampicin. As Dovato is a fixed-dose tablet, an additional 50&nbsp;mg tablet of dolutegravir should be administered, approximately 12&nbsp;hours after Dovato for the duration of the rifampicin co-administration (a separate formulation of dolutegravir is available for this dose adjustment, see section 4.2).</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Rifabutin/Dolutegravir</p></td><td style="vertical-align:top"><p>Dolutegravir &laquo;<br />&nbsp;&nbsp; AUC &macr; 5%<br />&nbsp;&nbsp; C<sub>max</sub> &shy; 16%<br />&nbsp;&nbsp; C&tau; &macr; 30%</p><p>(induction of UGT1A1 and CYP3A enzymes)</p></td><td colspan="2" style="vertical-align:top"><p>No dose adjustment is necessary.</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Anticonvulsants</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Carbamazepine/Dolutegravir</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;<br />&nbsp;&nbsp; AUC &macr; 49%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 33%<br />&nbsp;&nbsp; Ct &macr; 73%</p><p>&nbsp;</p></td><td colspan="2" rowspan="2" style="vertical-align:top"><p>The recommended dose of dolutegravir is 50&nbsp;mg twice daily when co‑administered with these metabolic inducers. As Dovato is a fixed-dose tablet, an additional 50&nbsp;mg tablet of dolutegravir should be administered, approximately 12&nbsp;hours after Dovato for the duration of the co-administration with these metabolic inducers (a separate formulation of dolutegravir is available for this dose adjustment, see section 4.2).</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Phenobarbital/Dolutegravir</p><p>Phenytoin/Dolutegravir</p><p>Oxcarbazepine/Dolutegravir</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;</p><p>(Not studied, decrease expected due to induction of UGT1A1 and CYP3A enzymes, a similar reduction in exposure as observed with carbamazepine is expected).</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Antihistamines (histamine H2 receptor antagonists)</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Ranitidine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Clinically significant interaction unlikely.</p></td><td colspan="2" style="vertical-align:top"><p>No dosage adjustment necessary.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Cimetidine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Clinically significant interaction unlikely.</p></td><td colspan="2" style="vertical-align:top"><p>No dosage adjustment necessary.</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Cytotoxics</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Cladribine/Lamivudine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p><em>In vitro</em> lamivudine inhibits the intracellular phosphorylation of cladribine leading to a potential risk of cladribine loss of efficacy in case of combination in the clinical setting. Some clinical findings also support a possible interaction between lamivudine and cladribine.</p></td><td colspan="2" style="vertical-align:top"><p>Concomitant use of Dovato with cladribine is not recommended (see section 4.4).</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Miscellaneous</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Sorbitol</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Sorbitol solution (3.2&nbsp;g, 10.2&nbsp;g, 13.4&nbsp;g)/Lamivudine</p></td><td style="vertical-align:top"><p>Single dose lamivudine oral solution 300&nbsp;mg.</p><p>Lamivudine:</p><p>AUC &macr; 14%; 32%; 36%</p><p>C<sub>max</sub> &macr; 28%; 52%, 55%.</p></td><td colspan="2" style="vertical-align:top"><p>When possible, avoid chronic coadministration of Dovato with medicinal products containing sorbitol or other osmotic acting poly-alcohols or monosaccharide alcohols (e.g.: xylitol, mannitol, lactitol, maltitol). Consider more frequent monitoring of HIV-1 viral load when chronic coadministration cannot be avoided.</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Potassium channel blockers</em></p></td></tr><tr><td style="vertical-align:top"><p>Fampridine (also known as dalfampridine)/Dolutegravir</p></td><td colspan="3" style="vertical-align:top"><p>Fampridine &shy;<br />&nbsp;</p></td><td style="vertical-align:top"><p>Co-administration of dolutegravir has the potential to cause seizures due to increased fampridine plasma concentration via inhibition of OCT2 transporter; co-administration has not been studied. Fampridine co-administration with Dovato is contraindicated (see section 4.3).</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Antacids and supplements</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Magnesium/</p><p>aluminium‑containing antacids/Dolutegravir</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;<br />AUC &macr; 74%<br />C<sub>max</sub> &macr; 72%<br />&nbsp;</p><p>(Complex binding to polyvalent ions)</p></td><td colspan="2" style="vertical-align:top"><p>Magnesium/ aluminium-containing antacids should be taken well separated in time from the administration of Dovato (minimum 2&nbsp;hours after or 6&nbsp;hours before).</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Calcium supplements/Dolutegravir<br />(fasted intake)</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;<br />&nbsp;&nbsp; AUC &macr; 39%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 37%<br />&nbsp;&nbsp; C<sub>24</sub> &macr; 39%</p><p>(Complex binding to polyvalent ions)</p></td><td colspan="2" rowspan="3" style="vertical-align:top"><p>- When taken with food, Dovato and supplements or multivitamins containing calcium, iron or magnesium can be taken at the same time.</p><p>- If Dovato is taken in a fasted state, such supplements should be taken a minimum 2&nbsp;hours after or 6&nbsp;hours before the intake of Dovato.</p><p>&nbsp;</p><p>The stated reductions in dolutegravir exposure were observed with the intake of dolutegravir and these supplements during fasted conditions. In fed state, the changes in exposure following intake together with calcium or iron supplements were modified by the food effect, resulting in an exposure similar to that obtained with dolutegravir administered in the fasted state.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Iron supplements/Dolutegravir<br />(fasted intake)</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;<br />&nbsp;&nbsp; AUC &macr; 54%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 57%<br />&nbsp;&nbsp; C<sub>24</sub> &macr; 56%</p><p>(Complex binding to polyvalent ions)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Multivitamins (containing calcium, iron and magnesium) /Dolutegravir<br />(fasted intake)</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;</p><p>&nbsp;&nbsp; AUC &macr; 33%</p><p>&nbsp;&nbsp; C<sub>max</sub> &macr; 35%</p><p>&nbsp;&nbsp; C<sub>24</sub> &macr; 32%</p><p>(Complex binding to polyvalent ions)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Proton pump inhibitors</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Omeprazole</p></td><td style="vertical-align:top"><p>Dolutegravir &laquo;</p></td><td colspan="2" style="vertical-align:top"><p>No dosage adjustment necessary.</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Corticosteroids</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Prednisone/Dolutegravir</p></td><td style="vertical-align:top"><p>Dolutegravir &laquo;</p><p>&nbsp;&nbsp; AUC &shy; 11%</p><p>&nbsp;&nbsp; C<sub>max</sub> &shy; 6%</p><p>&nbsp;&nbsp; C&tau; &shy; 17%</p></td><td colspan="2" style="vertical-align:top"><p>No dose adjustment is necessary.</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Antidiabetics</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Metformin/Dolutegravir</p></td><td style="vertical-align:top"><p>Metformin &shy;</p><p>Dolutegravir &laquo;</p><p>When co-administered with dolutegravir 50&nbsp;mg QD:</p><p>Metformin<br />&nbsp;&nbsp; AUC &shy; 79%<br />&nbsp;&nbsp; C<sub>max</sub> &shy; 66%</p><p>When co-administered with dolutegravir 50&nbsp;mg BID:</p><p>&nbsp;&nbsp; Metformin<br />&nbsp;&nbsp; AUC &shy; 145 %<br />&nbsp;&nbsp; C<sub>max</sub> &shy; 111%</p></td><td colspan="2" style="vertical-align:top"><p>A dose adjustment of metformin should be considered when starting and stopping coadministration of Dovato with metformin, to maintain glycaemic control. In patients with moderate renal impairment a dose adjustment of metformin should be considered when coadministered with Dovato, because of the increased risk for lactic acidosis in patients with moderate renal impairment due to increased metformin concentration (section 4.4).</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Herbal products</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>St. John&rsquo;s wort/Dolutegravir</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dolutegravir &macr;</p><p>(Not studied, decrease expected due to induction of UGT1A1 and CYP3A enzymes, a similar reduction in exposure as observed with carbamazepine is expected).</p></td><td colspan="2" style="vertical-align:top"><p>The recommended dose of dolutegravir is 50&nbsp;mg twice daily when co-administered with St. John&rsquo;s wort. As Dovato is a fixed-dose tablet, an additional 50&nbsp;mg tablet of dolutegravir should be administered, approximately 12&nbsp;hours after Dovato for the duration of the St. John&rsquo;s wort co-administration (a separate formulation of dolutegravir is available for this dose adjustment, see section 4.2).</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><em>Oral contraceptives</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Ethinyl estradiol (EE) and Norgestromin (NGMN)/Dolutegravir</p></td><td style="vertical-align:top"><p>Effect of dolutegravir:</p><p>EE &laquo;<br />&nbsp;&nbsp; AUC &shy; 3%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 1%<br />&nbsp;</p><p>Effect of dolutegravir:</p><p>NGMN &laquo;<br />&nbsp;&nbsp; AUC &macr; 2%<br />&nbsp;&nbsp; C<sub>max</sub> &macr; 11%</p></td><td colspan="2" style="vertical-align:top"><p>Dolutegravir had no pharmacodynamic effect on Luteinizing Hormone (LH), Follicle Stimulating Hormone (FSH) and progesterone. No dose adjustment of oral contraceptives is necessary when co-administered with Dovato.</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><strong>Paediatric population</strong></p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p>Dovato can be used during pregnancy if clinically needed.</p><p>A large amount of data on pregnant women (more than 1000 exposed outcomes) indicate no malformative nor feto/ neonatal toxicity associated with dolutegravir. A large amount of data on pregnant women (more than 1000 exposed outcomes) indicate no malformative nor feto/neonatal toxicity with lamivudine.</p><p>There are no or limited amount of data (less than 300 exposed outcomes) from the use of this dual combination in pregnancy.</p><p>The safety and efficacy of a dual therapy with dolutegravir + lamivudine has not been studied in pregnancy.Two large birth outcome surveillance studies (more than 14,000 pregnancy outcomes) in Botswana (Tsepamo) and Eswatini, and other sources, do not indicate an increased risk for neural tube defects after dolutegravir exposure.</p><p>The incidence of neural tube defects in the general population ranges from 0.5-1 case per 1,000 live births (0.05-0.1%).</p><p>Data from the Tsepamo study show no significant difference in the prevalence of neural tube defects (0.11%) in infants whose mothers were taking dolutegravir at conception (more than 9,400 exposures) compared to those taking non-dolutegravir containing antiretroviral regimens at conception (0.11%), or compared to women without HIV (0.07%).</p><p>Data from the Eswatini study show the same prevalence of neural tube defects (0.08%) in infants whose mothers were taking dolutegravir at conception (more than 4,800 exposures), as infants of women without HIV (0.08%).</p><p>&nbsp;</p><p>Data analysed from the Antiretroviral Pregnancy Registry (APR) of more than 1000 pregnancies with first trimester dolutegravir treatment and more than 1000 pregnancies with first trimester lamivudine treatment, do not indicate an increased risk of major birth defects with either dolutegravir or lamivudine compared to the background rate or women with HIV &nbsp;There are no or limited amount of APR data (less than 300 first trimester exposures) from the use of dolutegravir + lamivudine in pregnant women.</p><p>&nbsp;</p><p>In animal reproductive toxicology studies with dolutegravir, no adverse development outcomes, including neural tube defects, were identified (see section 5.3).</p><p>&nbsp;</p><p>Dolutegravir readily crosses the placenta in humans. In HIV-infected pregnant women, the median (range) foetal umbilical cord concentrations of dolutegravir were 1.28 (1.21 to 1.28) fold greater compared with maternal peripheral plasma concentrations.</p><p>&nbsp;</p><p>There is insufficient information on the effects of dolutegravir on neonates.</p><p>&nbsp;</p><p>Animal studies with lamivudine showed an increase in early embryonic deaths in rabbits but not in rats (see section 5.3).</p><p>&nbsp;</p><p>Animal studies showed lamivudine may inhibit cellular DNA replication (see section 5.3). The clinical relevance of these findings is unknown.</p><p>&nbsp;</p><p><em>Mitochondrial dysfunction</em></p><p>Nucleoside and nucleotide analogues have been demonstrated <em>in vitro</em> and <em>in vivo</em> to cause a variable degree of mitochondrial damage. There have been reports of mitochondrial dysfunction in HIV-negative infants exposed <em>in utero</em> and/or post-natally to nucleoside analogues (see section 4.4).</p><p>&nbsp;</p><p><strong>Breast-feeding </strong></p><p>Dolutegravir is excreted in human milk in small amounts (a median dolutegravir breast milk to maternal plasma ratio of 0.033 has been shown). There is insufficient information on the effects of dolutegravir in neonates/infants.</p><p>&nbsp;</p><p>Based on more than 200 mother/child pairs treated for HIV, serum concentrations of lamivudine in breastfed infants of mothers treated for HIV are very low (&lt; 4% of maternal serum concentrations) and progressively decrease to undetectable levels when breastfed infants reach 24&nbsp;weeks of age. There are no data available on the safety of lamivudine when administered to babies less than three months old.</p><p>&nbsp;</p><p>It is recommended that women living with HIV do not breast-feed their infants in order to avoid transmission of HIV.</p><p>&nbsp;</p><p><strong>Fertility </strong></p><p>There are no data on the effects of dolutegravir or lamivudine on human male or female fertility. Animal studies indicate no effects of dolutegravir or lamivudine on male or female fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dovato has no or negligible influence on the ability to drive and use machines. Patients should be informed that dizziness and somnolence has been reported during treatment with dolutegravir. The clinical status of the patient and the adverse reaction profile of Dovato should be borne in mind when considering the patient&rsquo;s ability to drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p><strong>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Summary of the safety profile</strong></p><p>The most frequently reported adverse reactions are headache (3%), diarrhoea (2%), nausea (2%) and insomnia (2%).</p><p>&nbsp;</p><p>The most severe adverse reaction reported with dolutegravir was a hypersensitivity reaction that included rash and severe liver effects (see section 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Tabulated summary of adverse reactions</strong></p><p>The adverse reactions from clinical study and post-marketing experience are listed in Table&nbsp;2 by body system, organ class and absolute frequency. Frequencies are defined as very common (&sup3;1/10), common (&sup3;1/100 to &lt;1/10), uncommon (&sup3;1/1,000 to &lt;1/100), rare (&sup3;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p><strong>Table 2:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tabulated summary of adverse reactions to Dovato based on clinical study and post-marketing experience with Dovato and its individual components&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:535px"><tbody><tr><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Blood and lymphatic systems disorders:</em></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>neutropenia, anaemia, thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>pure red cell aplasia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Immune system disorders:</em></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>hypersensitivity (see section 4.4), immune reconstitution syndrome (see section 4.4)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Metabolism and nutrition disorders:</em></p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>lactic acidosis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Psychiatric disorders: </em></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>depression, anxiety, insomnia, abnormal dreams</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>suicidal ideation*, suicide attempt*, panic attack<br /><br />*particularly in patients with a pre-existing history of depression or psychiatric illness.</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>completed suicide*</p><p>&nbsp;</p><p>*particularly in patients with a pre-existing history of depression or psychiatric illness.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Nervous system disorders: </em></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>headache</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>dizziness, somnolence</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>peripheral neuropathy, paraesthesia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Gastrointestinal disorders: </em></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>nausea, diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>vomiting, flatulence, abdominal pain/ discomfort</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>pancreatitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Hepatobiliary disorders:</em></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) elevations</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>hepatitis</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>acute hepatic failure<sup>1</sup>, increased bilirubin<sup>2</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Skin and subcutaneous tissue disorders: </em></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>rash, pruritus, alopecia</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>angioedema</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Musculoskeletal and connective tissue disorders:</em></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>arthralgia, muscle disorders (including myalgia)</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>rhabdomyolysis</p></td></tr><tr><td style="vertical-align:top"><p>Not Known:</p></td><td style="vertical-align:top"><p>creatinine phosphokinase elevation</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>General disorders and administration site conditions: </em></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>fatigue</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Investigations:</em></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>creatine phosphokinase (CPK) elevations, weight increased</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>amylase elevations</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><sup>1</sup> This adverse reaction was identified through post-marketing surveillance for dolutegravir in combination with other ARVs. The frequency category of rare was estimated based on post-marketing reports.</p><p><sup>2</sup> In combination with increased transaminases.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Description of selected adverse reactions</strong></p><p><strong>Changes in laboratory biochemistries</strong></p><p>Dolutegravir has been associated with an increase in serum creatinine occuring in the first week of treatment when administered with other antiretroviral medicinal products. Increases in serum creatinine occurred within the first four weeks of treatment with dolutegravir plus lamivudine and remained stable through 48&nbsp;weeks. In the pooled GEMINI studies a mean change from baseline of 10.3&nbsp;&micro;mol/L (range:&nbsp;‑36.3&nbsp;&micro;mol/L to 55.7&nbsp;&micro;mol/L) was observed after 48&nbsp;weeks of treatment. These changes are linked to the inhibiting effect of dolutegravir on renal tubular transporters of creatinine. The changes are not considered to be clinically relevant and do not reflect a change in glomerular filtration rate.</p><p>&nbsp;</p><p><strong>Co-infection with Hepatitis B or C</strong></p><p>In the Phase III studies for the dolutegravir single agent, patients with hepatitis B and/or C co-infection were permitted to enrol provided that baseline liver chemistry tests did not exceed 5 times the upper limit of normal (ULN). Overall, the safety profile in patients co-infected with hepatitis B and/or C was similar to that observed in patients without hepatitis B or C co-infection, although the rates of AST and ALT abnormalities were higher in the subgroup with hepatitis B and/or C co-infection for all treatment groups. Liver chemistry elevations consistent with immune reconstitution syndrome were observed in some subjects with hepatitis B and/or C co-infection at the start of dolutegravir therapy, particularly in those whose anti-hepatitis B therapy was withdrawn (see section 4.4).</p><p>&nbsp;</p><p><strong>Metabolic parameters </strong></p><p>Weight and levels of blood lipids and glucose may increase during antiretroviral therapy (see section 4.4).</p><p><em>&nbsp;</em></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Osteonecrosis </strong></p><p>Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV disease or long-term exposure to CART. The frequency of this is unknown (see section 4.4).</p><p><em>&nbsp;</em></p><p><strong>Immune response syndrome</strong></p><p>In HIV-infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise. Autoimmune disorders (such as Graves&rsquo; disease and autoimmune hepatitis) have also been reported; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section 4.4).</p><p>&nbsp;</p><p><strong>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Paediatric population</strong></p><p>There are no clinical study data on the effects of Dovato in the paediatric population. Individual components have been investigated in adolescents (12 to 17 years).</p><p>&nbsp;</p><p>Based on limited available data with the dolutegravir single entity or lamivudine single entity used in combination with other antiretroviral agents to treat adolescents (12 to 17 years), there were no additional types of adverse reactions beyond those observed in the adult population.</p><p>&nbsp;</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the bellow channels:</p><p>&nbsp;</p><p><strong><u>To report any side effect(s):</u></strong></p><p><strong><em>Kingdom of Saudi Arabia</em></strong></p><p><strong>-The National Pharmacovigilance Centre (NPC)</strong></p><p>&middot;&nbsp;&nbsp; SFDA Call Centre: 19999</p><p>&middot;&nbsp;&nbsp; E-mail : &nbsp;npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p><p><strong>-GSK - Head Office, Jeddah</strong></p><p>&middot;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666</p><p>&middot;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&middot;&nbsp;&nbsp; Email: saudi.safety@gsk.com</p><p>&middot;&nbsp;&nbsp; Website: https://gskpro.com/en-sa/<u> </u></p><p>&middot;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p><p><strong><u>For any information about this medicinal product, please contact:</u></strong></p><p><strong>GSK- Head Office, Jeddah</strong></p><p>&middot;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666</p><p>&middot;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&middot;&nbsp;&nbsp; Email: gcc.medinfo@gsk.com&nbsp;</p><p>&middot;&nbsp;&nbsp; Website: https://gskpro.com/en-sa/<u> </u>&nbsp;&nbsp;</p><p>&middot;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific symptoms or signs have been identified following acute overdose with dolutegravir or lamivudine, apart from those listed as adverse reactions.</p><p>&nbsp;</p><p>There is no specific treatment for an overdose of Dovato. If overdose occurs, the patient should be treated supportively with appropriate monitoring, as necessary. Since lamivudine is dialysable, continuous haemodialysis could be used in the treatment of overdose, although this has not been studied. As dolutegravir is highly bound to plasma proteins, it is unlikely that it will be significantly removed by dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group</strong>: Antivirals for systemic use, antivirals for treatment of HIV infections, combinations. ATC code: J05AR25</p><p><strong>Mechanism of action</strong></p><p>Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral Deoxyribonucleic acid (DNA) integration which is essential for the HIV replication cycle.</p><p>&nbsp;</p><p>Lamivudine, via its active metabolite 5&#39;-triphosphates (TP) (an analogue for cytidine), inhibits reverse transcriptase of HIV-1 and HIV-2 through incorporation of the monophosphate form into the viral DNA chain, resulting in chain termination. Lamivudine triphosphate shows significantly less affinity for host cell DNA polymerases.</p><p>&nbsp;</p><p><strong>Pharmacodynamic effects</strong></p><p><em>Antiviral activity in cell culture </em></p><p>Dolutegravir and lamivudine have been shown to inhibit replication of lab-strains and clinical isolates of HIV in a number of cell types, including transformed T cell lines, monocyte/macrophage derived lines and primary cultures of activated peripheral blood mononuclear cells (PMBCs) and monocyte/macrophages. The concentration of active substance necessary to effect viral replication by 50% (IC<sub>50</sub> - half maximal inhibitory concentration) varied according to virus and host cell type.</p><p>&nbsp;</p><p>The IC<sub>50</sub> for dolutegravir in various lab-strains using PBMC was 0.5&nbsp;nM, and when using MT-4 cells it ranged from 0.7-2&nbsp;nM. Similar IC<sub>50</sub>s were seen for clinical isolates without any major difference between subtypes; in a panel of 24 HIV-1 isolates of clades A, B, C, D, E, F and G and group O the mean IC<sub>50</sub> value was 0.2&nbsp;nM (range 0.02-2.14). The mean IC<sub>50</sub> for 3 HIV-2 isolates was 0.18&nbsp;nM (range 0.09‑0.61).</p><p>&nbsp;</p><p>The median or mean IC<sub>50</sub> values for lamivudine against lab-strains of HIV-1 ranged from 0.007 to 2.3&nbsp;mM. The mean IC<sub>50</sub> against lab-strains of HIV-2 (LAV2 and EHO) ranged from 0.16 to 0.51&nbsp;mM for lamivudine. The IC<sub>50</sub> values of lamivudine against HIV-1 subtypes (A-G) ranged from 0.001 to 0.170&nbsp;mM, against Group O from 0.030 to 0.160&nbsp;mM and against HIV-2 isolates from 0.002 to 0.120&nbsp;mM in peripheral blood mononuclear cells.</p><p>&nbsp;</p><p>HIV-1 isolates (CRF01_AE, n=12; CRF02_AG, n=12; and Subtype C or CRF_AC, n=13) from 37 untreated patients in Africa and Asia were susceptible to lamivudine (IC<sub>50</sub> fold changes &lt; 3.0). Group O isolates from antiviral na&iuml;ve patients tested for lamivudine activity were highly sensitive.</p><p>&nbsp;</p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>Effect of human serum </em></p><p>In 100% human serum, the mean fold shift for dolutegravir activity was 75&nbsp;fold, resulting in protein adjusted IC<sub>90</sub> of 0.064&nbsp;mg/mL. Lamivudine exhibits linear pharmacokinetics over the therapeutic dose range and displays low plasma protein binding (less than 36%).<em> </em></p><p>&nbsp;</p><p><strong>Resistance</strong></p><p>Dovato is indicated in the absence of documented or suspected resistance to the integrase inhibitor class and to lamivudine (see section 4.1). For information around in vitro resistance, and cross resistance to other agents of the integrase- and NRTI class, please refer to the SmPCs of dolutegravir and lamivudine.</p><p>&nbsp;</p><p>None of the twelve subjects in the dolutegravir plus lamivudine group or the nine subjects in the dolutegravir plus tenofovir disoproxil/emtricitabine FDC group that met virological withdrawal criteria through Week 144 across the GEMINI-1 (204861) and GEMINI-2 (205543) studies had treatment emergent integrase inhibitor or NRTI class resistance.</p><p>&nbsp;</p><p>In previously untreated patients receiving dolutegravir + 2 NRTIs in Phase IIb and Phase III, no development of resistance to the integrase inhibitor class, or to the NRTI class was seen (n=1118 follow-up of 48‑96&nbsp;weeks).</p><p>&nbsp;</p><p><strong>Effects on electrocardiogram</strong></p><p>No relevant effects were seen with dolutegravir on the QTc interval, with doses exceeding the clinical dose by approximately three-fold. A similar study was not conducted with lamivudine.</p><p>&nbsp;</p><p><strong>Clinical efficacy and safety </strong></p><p><em>Antiretroviral na&iuml;ve subjects</em></p><p>The efficacy of Dovato is supported by data from 2 identical 148-week, Phase III, randomised, double-blind, multicentre, parallel-group, non-inferiority controlled trials GEMINI-1 (204861) and GEMINI-2 (205543). A total of 1433 HIV-1 infected antiretroviral treatment-na&iuml;ve adult subjects received treatment in the trials. Subjects were enrolled with a screening plasma HIV-1 RNA of 1000&nbsp;c/mL to &le;500,000&nbsp;c/mL. Subjects were randomised to a two-drug regimen of dolutegravir 50&nbsp;mg plus lamivudine 300&nbsp;mg once daily or dolutegravir 50&nbsp;mg plus tenofovir disoproxil/emtricitabine 245/200&nbsp;mg once daily. The primary efficacy endpoint for each GEMINI trial was the proportion of subjects with plasma HIV-1 RNA &lt;50&nbsp;copies/mL at Week&nbsp;48 (Snapshot algorithm for the ITT-E population). Double blind therapy continued up to week 96, followed by open label therapy up to week 148.</p><p>&nbsp;</p><p>At baseline, in the pooled analysis, the median age of subjects was 33 years, 15% were female, 69% were white, 9% were CDC Stage 3 (AIDS), 20% had HIV-1 RNA &gt;100,000&nbsp;copies/mL, and 8% had CD4+ cell count less than 200&nbsp;cells per mm<sup>3</sup>; these characteristics were similar between studies and treatment arms.</p><p>&nbsp;</p><p>In the primary week 48 analysis, dolutegravir plus lamivudine was non-inferior to dolutegravir plus tenofovir disoproxil/emtricitabine FDC in GEMINI-1 and GEMINI-2 studies. This was supported by the pooled analysis, see Table 3.</p><p><strong>Table 3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Virologic Outcomes of Randomised Treatment of GEMINI at Week&nbsp;48 (Snapshot algorithm)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:577px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>GEMINI-1 and GEMINI-2 Pooled Data</strong>*</p></td></tr><tr><td style="vertical-align:top"><p><strong>DTG + 3TC</strong></p><p><strong>N=716</strong></p></td><td style="vertical-align:top"><p><strong>DTG + TDF/FTC</strong></p><p><strong>N=717</strong></p></td></tr><tr><td><p><strong>HIV-1 RNA &lt;50&nbsp;copies/mL</strong></p></td><td style="vertical-align:top"><p>91%</p></td><td style="vertical-align:top"><p>93%</p></td></tr><tr><td><p><strong>&nbsp;Treatment Difference</strong><sup>&dagger; </sup>(95%<sup> </sup>confidence intervals)</p></td><td colspan="2" style="vertical-align:top"><p>-1.7 (-4.4, 1.1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Virologic non response</strong></p></td><td><p>3%</p></td><td style="vertical-align:top"><p>2%</p></td></tr><tr><td style="vertical-align:top"><p><u>Reasons</u></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Data in window and &ge;50&nbsp;copies/mL</p></td><td><p>1%</p></td><td><p>&lt;1%</p></td></tr><tr><td><p>Discontinued for lack of efficacy</p></td><td><p>&lt;1%</p></td><td><p>&lt;1%</p></td></tr><tr><td style="vertical-align:top"><p>Discontinued for other reasons and &ge;50&nbsp;copies/mL</p></td><td><p>&lt;1%</p></td><td><p>&lt;1%</p></td></tr><tr><td style="vertical-align:top"><p>Change in ART</p></td><td><p>&lt;1%</p></td><td><p>&lt;1%</p></td></tr><tr><td style="vertical-align:top"><p><strong>No virologic data at Week 48 window</strong></p></td><td><p>6%</p></td><td><p>5%</p></td></tr><tr><td style="vertical-align:top"><p><u>Reasons</u></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Discontinued study due to adverse event or death</p></td><td><p>1%</p></td><td><p>2%</p></td></tr><tr><td><p>Discontinued study for other reasons</p></td><td><p>4%</p></td><td><p>3%</p></td></tr><tr><td style="vertical-align:top"><p>Missing data during window but on study</p></td><td><p>&lt;1%</p></td><td><p>0%</p></td></tr><tr><td colspan="3"><p><strong>HIV-1 RNA &lt;50&nbsp;copies/mL by baseline covariates</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>n/N (%)</p></td><td><p>n/N (%)</p></td></tr><tr><td><p><strong>Baseline Plasma Viral Load (copies/mL)</strong></p><p>&le;100,000</p><p>&gt;100,000</p></td><td><p><br />526 / 576 (91%)<br />129 / 140 (92%)</p></td><td><p><br />531 / 564 (94%)<br />138 / 153 (90%)</p></td></tr><tr><td><p><strong>Baseline CD4+ (cells/ mm<sup>3</sup>)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&le;200</p></td><td><p>50 / 63 (79%)</p></td><td><p>51 / 55 (93%)</p></td></tr><tr><td><p>&nbsp;&gt;200</p></td><td><p>605 / 653 (93%)</p></td><td><p>618 / 662 (93%)</p></td></tr><tr><td><p><strong>HIV-1 subtype</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;B</p></td><td><p>424 / 467 (91%)</p></td><td><p>452 / 488 (93%)</p></td></tr><tr><td><p>&nbsp;A</p></td><td><p>84 / 86 (98%)</p></td><td><p>74 / 78 (95%)</p></td></tr><tr><td><p>&nbsp;Other</p></td><td><p>147 / 163 (90%)</p></td><td><p>143 / 151 (95%)</p></td></tr><tr><td><p><strong>Gender</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;Male</p></td><td><p>555 / 603 (92%)</p></td><td><p>580 / 619 (94%)</p></td></tr><tr><td><p>&nbsp;Female</p></td><td><p>100 / 113 (88%)</p></td><td><p>89 / 98 (91%)</p></td></tr><tr><td><p><strong>Race </strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;White</p></td><td><p>451 / 484 (93%)</p></td><td><p>473 / 499 (95%)</p></td></tr><tr><td><p>&nbsp;African-American/African Heritage/Other</p></td><td><p>204 / 232 (88%)</p></td><td><p>196 / 218 (90%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>* The results of the pooled analysis are in line with those of the individual studies, for which the primary endpoint (difference in proportion &lt;50&nbsp;copies/mL plasma HIV-1 RNA at Week 48 based on the Snapshot algorithm for dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil /emtricitabine FDC) was met. The adjusted difference was -2.6 (95% CI: -6.7; 1.5) for GEMINI-1 and -0.7 (95% CI: -4.3; 2.9) for GEMINI-2 with a prespecified non-inferiority margin of 10%.</p><p>&dagger; Based on CMH-stratified analysis adjusting for the following baseline stratification factors: Plasma HIV-1 RNA (&le;100,000&nbsp;c/mL vs. &gt;100,000&nbsp;c/mL) and CD4+ cell count (&le;200&nbsp;cells/mm<sup>3</sup>&nbsp;vs.&nbsp;&gt;200&nbsp;cells/mm<sup>3</sup>).&nbsp;Pooled analysis also stratified by study. Assessed using a non‑inferiority margin of 10%.</p><p>N = Number of subjects in each treatment group</p></td></tr></tbody></table><p>&nbsp;</p><p>At 96 weeks and at 144 weeks in the GEMINI studies, the lower bound of the 95% confidence interval for the adjusted treatment difference of proportion of subjects with HIV-1 RNA &lt;50 copies/mL (Snapshot) was greater than the non-inferiority margin of -10%, for the individual studies as well as pooled analysis, see Table 4.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table 4</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Virologic Outcomes of Randomised Treatment of GEMINI at Weeks&nbsp;96 and 144 (Snapshot algorithm)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:595px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p><strong>GEMINI-1 and GEMINI-2 Pooled Data</strong>*</p></td></tr><tr><td style="vertical-align:top"><p><strong>DTG + 3TC</strong></p><p><strong>N=716</strong></p></td><td style="vertical-align:top"><p><strong>DTG + TDF/FTC</strong></p><p><strong>N=717</strong></p></td><td style="vertical-align:top"><p><strong>DTG + 3TC</strong></p><p><strong>N=716</strong></p></td><td style="vertical-align:top"><p><strong>DTG + TDF/FTC</strong></p><p><strong>N=717</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p>Week 96</p></td><td colspan="2" style="vertical-align:top"><p>Week 144</p></td></tr><tr><td><p><strong>HIV-1 RNA &lt;50&nbsp;copies/mL</strong></p></td><td style="vertical-align:top"><p>86%</p></td><td style="vertical-align:top"><p>90%</p></td><td style="vertical-align:top"><p>82%</p></td><td style="vertical-align:top"><p>84%</p></td></tr><tr><td><p><strong>&nbsp;Treatment Difference</strong><sup>&dagger; </sup><br />(95%<sup> </sup>confidence intervals)</p></td><td colspan="2"><p>-3.4% (-6.7, 0.0)</p></td><td colspan="2"><p>-1.8% (-5.8; 2.1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Virologic non response</strong></p></td><td><p>3%</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>3%</p></td><td style="vertical-align:top"><p>3%</p></td></tr><tr><td style="vertical-align:top"><p><u>Reasons</u></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Data in window, &ge;50&nbsp;cps/mL</p></td><td><p>&lt;1%</p></td><td><p>&lt;1%</p></td><td style="vertical-align:top"><p>&lt;1%</p></td><td style="vertical-align:top"><p>&lt;1%</p></td></tr><tr><td><p>Discontinued, lack of efficacy</p></td><td><p>1%</p></td><td><p>&lt;1%</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>&lt;1%</p></td></tr><tr><td style="vertical-align:top"><p>Discontinued, other reasons, &ge;50&nbsp;cps/mL</p></td><td><p>&lt;1%</p></td><td><p>&lt;1%</p></td><td style="vertical-align:top"><p>&lt;1%</p></td><td style="vertical-align:top"><p>2%</p></td></tr><tr><td style="vertical-align:top"><p>Change in ART</p></td><td><p>&lt;1%</p></td><td><p>&lt;1%</p></td><td style="vertical-align:top"><p>&lt;1%</p></td><td style="vertical-align:top"><p>&lt;1%</p></td></tr><tr><td style="vertical-align:top"><p><strong>No virologic data at Week 96/Week 144 window</strong></p><p><u>Reasons</u></p><p>Discontinued study due to AE or death</p><p>Discontinued study for other reasons</p><p>Loss to follow-up</p><p>Withdrew consent</p><p>Protocol deviations</p><p>Physicians decision</p><p>Missing data in window, on study</p></td><td style="vertical-align:top"><p>11%</p><p>&nbsp;</p><p>&nbsp;</p><p>3%</p><p>8%</p><p>3%</p><p>3%</p><p>1%</p><p>1%</p><p>0%</p></td><td style="vertical-align:top"><p>9%</p><p>&nbsp;</p><p>&nbsp;</p><p>3%</p><p>5%</p><p>1%</p><p>2%</p><p>1%</p><p>&lt;1%</p><p>&lt;1%</p></td><td style="vertical-align:top"><p>15%</p><p>&nbsp;</p><p>&nbsp;</p><p>4%</p><p>11%</p><p>3%</p><p>4%</p><p>2%</p><p>2%</p><p>&lt;1%</p></td><td style="vertical-align:top"><p>14%</p><p>&nbsp;</p><p>&nbsp;</p><p>4%</p><p>9%</p><p>3%</p><p>3%</p><p>1%</p><p>1%</p><p>&lt;1%</p></td></tr></tbody></table><p>*<em> </em>The results of the pooled analysis are in line with those of the individual studies.</p><p>&dagger; Based on CMH-stratified analysis adjusting for the following baseline stratification factors: Plasma HIV-1 RNA (&le;100,000&nbsp;c/mL vs. &gt;100,000&nbsp;c/mL) and CD4+ cell count (&le;200&nbsp;cells/mm<sup>3</sup>&nbsp;vs.&nbsp;&gt;200&nbsp;cells/mm<sup>3</sup>). Pooled analysis also stratified by study. Assessed using a non‑inferiority margin of 10%.</p><p>N = Number of subjects in each treatment group</p><p>The mean increase in CD4+ T-cell counts through week 144 was 302 cells/mm<sup>3</sup> in the dolutegravir plus lamivudine arm and 300 cells/mm<sup>3</sup> in the dolutegravir plus tenofovir/emtricitabine arm.</p><p>&nbsp;<!--[if supportFields]><span
style='mso-bookmark:_Hlk522785098'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Hlk522785098'><span dir=LTR></span><span dir=LTR></span><span
style='mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB'><span
dir=LTR></span><span dir=LTR></span><span
style='mso-spacerun:yes'> </span>DOCVARIABLE
vault_nd_9121d242-7efd-4151-b3cf-509864ab8930 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bookmark:_Hlk522785098'></span><span style='mso-element:field-end'></span><![endif]--><strong>&nbsp;</strong></p><p><em>Virologically suppressed subjects</em></p><p>&nbsp;</p><p>The efficacy of dolutegravir/lamivudine in virologically suppressed subjects is supported by data from a randomised, open-label, trial (TANGO [204862]). A total of 741 adult HIV-1 infected subjects, without any evidence of resistance to the NRTI or integrase inhibitor (INSTI) class and who were on a stable suppressive tenofovir alafenamide based regimen (TBR) received treatment in the studies. Subjects were randomised in a 1:1 ratio to receive dolutegravir/lamivudine FDC or continue with TBR for up to 200 weeks. Randomisation was stratified by baseline core agent class (protease inhibitor [PI], INSTI, or non-nucleoside reverse transcriptase inhibitor [NNRTI]). The primary efficacy endpoint was the proportion of subjects with plasma HIV-1 RNA &ge;50 c/mL (virologic non-response) as per the FDA Snapshot category at Week 48 (adjusted for randomisation stratification factor).</p><p>&nbsp;</p><p>At baseline the median age of subjects was 39 years, 8% were female and 21% non-white, 5% were CDC Class C (AIDS) and 98% subjects had Baseline CD4+ cell count &ge;200 cells/mm<sup>3</sup>; these characteristics were similar between treatment arms. Subjects had been on ART for a median of around 3 years prior to Day 1 Around 80% were on INSTI-based TBR (mainly elvitegravir/c) at baseline.</p><p>In the primary 48-week analysis, dolutegravir/lamivudine was non-inferior to TBR, with &lt;1% of subjects in both arms experiencing virologic failure (HIV-1 RNA &ge;50 c/mL) (Table 5).</p><p><strong>Table 5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Virologic Outcomes of Randomised Treatment of TANGO at Week&nbsp;48 (Snapshot algorithm)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:577px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>DTG/3TC</strong></p><p><strong>N=369</strong></p></td><td style="vertical-align:top"><p><strong>TBR</strong></p><p><strong>N=372</strong></p></td></tr><tr><td><p><strong>HIV-1 RNA &lt;50 copies/mL*</strong></p></td><td style="vertical-align:top"><p>93%</p></td><td style="vertical-align:top"><p>93%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Virologic non response </strong>(&sup3;50 copies/mL)<strong>**</strong></p></td><td style="vertical-align:top"><p>&lt;1%</p></td><td style="vertical-align:top"><p>&lt;1%</p></td></tr><tr><td><p><strong>Treatment Difference</strong><sup>&dagger; </sup>(95%<sup> </sup>confidence intervals)</p></td><td colspan="2" style="vertical-align:top"><p>-0.3 (-1.2, 0.7)</p></td></tr><tr><td style="vertical-align:top"><p><u>Reasons for virologic non response:</u></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Data in window and &ge;50 copies/mL</p></td><td><p>0%</p></td><td><p>0%</p></td></tr><tr><td><p>Discontinued for lack of efficacy</p></td><td><p>0%</p></td><td><p>&lt;1%</p></td></tr><tr><td style="vertical-align:top"><p>Discontinued for other reasons and &ge;50 copies/mL</p></td><td><p>&lt;1%</p></td><td><p>0%</p></td></tr><tr><td style="vertical-align:top"><p>Change in ART</p></td><td><p>0%</p></td><td><p>0%</p></td></tr><tr><td style="vertical-align:top"><p><strong>No virologic data at Week 48 window</strong></p></td><td><p>7%</p></td><td><p>6%</p></td></tr><tr><td style="vertical-align:top"><p><u>Reasons</u></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Discontinued study due to adverse event or death</p></td><td><p>3%</p></td><td><p>&lt;1%</p></td></tr><tr><td><p>Discontinued study for other reasons</p></td><td><p>3%</p></td><td><p>6%</p></td></tr><tr><td style="vertical-align:top"><p>Missing data during window but on study</p></td><td><p>0%</p></td><td><p>&lt;1%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*Based on an 8% non-inferiority margin, DTG/3TC is non-inferior to TBR at Week 48 in the secondary analysis (proportion of subjects achieving &lt;50 copies/mL plasma HIV-1 RNA).</p><p>**Based on a 4% non-inferiority margin, DTG/3TC is non-inferior to TBR at Week 48 in the primary analysis (proportion of subjects with plasma HIV-1 RNA &ge;50 c/mL).</p><p>&dagger;Based on CMH-stratified analysis adjusting for Baseline third agent class (PI, NNRTI, INSTI).</p><p>N = Number of subjects in each treatment group; TBR = tenofovir alafenamide based regimen.<br />&nbsp;</p></td></tr></tbody></table><p>Treatment outcomes between treatment arms at week 48 were similar across the stratification factor, baseline third agent class&nbsp;and across subgroups by age, sex, race, baseline CD4+ cell count, CDC HIV disease stage, and countries. The median change from baseline in CD4+ count at Week 48 was 22.5 cells per mm<sup>3</sup> in subjects who switched to dolutegravir/lamivudine and 11.0 cells per mm<sup>3</sup> in subjects who stayed on TBR.</p><p>&nbsp;</p><p>At 96 weeks in the TANGO study, the proportion of subjects with HIV-1 RNA &ge;50 c/mL (Snapshot) was 0.3% and 1.1% in the dolutegravir/lamivudine and TBR groups, respectively. Based on a non-inferiority margin of 4%, dolutegravir/lamivudine remained non-inferior to TBR, as the upper bound of the 95% CI for the adjusted treatment difference (-2.0%; 0.4%) was less than 4% for the ITT E Population.</p><p>&nbsp;</p><p>The median change from baseline in CD4+ T-cell counts at week 96 was 61 cells/mm<sup>3 </sup>in the dolutegravir/lamivudine arm and 45 cells/mm<sup>3</sup> in the TBR arm.</p><p>&nbsp;</p><p>At 144 weeks, the proportion of subjects with HIV-1 RNA &ge;50 c/mL (Snapshot) was 0.3% and 1.3% in the dolutegravir/lamivudine and TBR groups, respectively. Based on a non-inferiority margin of 4%, dolutegravir/lamivudine remained non-inferior to TBR, as the upper bound of the 95% CI for the adjusted treatment difference (-2.4%, 0.2%) was less than 4% for the ITT E Population.</p><p>&nbsp;</p><p>The median change from baseline in CD4+ T-cell counts at Week 144 was 36 cells/mm<sup>3 </sup>in the dolutegravir/lamivudine arm and 35 cells/mm<sup>3</sup> in the TBR arm.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Paediatric population</strong></p><p>The efficacy of Dovato, or the dual combination of dolutegravir plus lamivudine (as single entities) has not been studied in children or adolescents.</p><p>&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with Dovato in one or more subsets of the paediatric population in the treatment of HIV infection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>When administered in fasted state, bioequivalence regarding C<sub>max</sub> was achieved for dolutegravir, when comparing Dovato to dolutegravir 50&nbsp;mg co-administered with lamivudine 300&nbsp;mg. Dolutegravir AUC<sub>0-t</sub> was 16% higher for Dovato than for dolutegravir 50&nbsp;mg co-administered with lamivudine 300&nbsp;mg. This increase is not considered clinically relevant.</p><p>&nbsp;</p><p>When administered in fasted state, bioequivalence was achieved for lamivudine AUC, when comparing Dovato to lamivudine 300&nbsp;mg co-administered with dolutegravir 50&nbsp;mg. Lamivudine C<sub>max</sub> for Dovato was 32% higher than lamivudine 300&nbsp;mg co-administered with dolutegravir 50&nbsp;mg. The higher lamivudine C<sub>max</sub>, is not considered clinically relevant.</p><p><strong>&nbsp;</strong></p><p><strong>Absorption </strong></p><p>Dolutegravir and lamivudine are rapidly absorbed following oral administration. The absolute bioavailability of dolutegravir has not been established. The absolute bioavailability of oral lamivudine in adults is approximately 80-85%. For Dovato, the median time to maximal plasma concentration (t<sub>max</sub>) is 2.5&nbsp;hours for dolutegravir and 1.0&nbsp;hour for lamivudine, when dosed under fasted conditions.<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_25623483-7410-4933-92bb-343bc77963f9 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>Exposure to dolutegravir was generally similar between healthy subjects and HIV‑1&ndash;infected subjects. In HIV‑1&ndash;infected adult subjects following dolutegravir 50&nbsp;mg once daily, the steady-state pharmacokinetic parameters (geometric mean [%CV]) based on population pharmacokinetic analyses were AUC<sub>(0‑24)</sub>&nbsp;=&nbsp;53.6&nbsp;(27)&nbsp;mg.h/mL, C<sub>max</sub>&nbsp;=&nbsp;3.67 (20)&nbsp;mg/mL, and C<sub>min</sub>&nbsp;=&nbsp;1.11 (46)&nbsp;mg/mL. Following multiple-dose oral administration of lamivudine 300&nbsp;mg once daily for seven days, the mean (CV) steady-state C<sub>max</sub> is 2.04&nbsp;&micro;g/mL (26%) and the mean (CV) AUC<sub>(0-24)</sub> is 8.87&nbsp;&micro;g.h/mL (21%).</p><p>&nbsp;</p><p>Administration of a single Dovato tablet with a high fat meal increased dolutegravir AUC<sub>(0-</sub><sub>&yen;</sub><sub>)</sub> and C<sub>max</sub> by 33% and 21%, respectively, and decreased the lamivudine C<sub>max</sub> by 30% compared to fasted conditions. The lamivudine AUC<sub>(0-</sub><sub>&yen;</sub><sub>)</sub> was not affected by a high fat meal. These changes are not clinically significant. Dovato may be administered with or without food.</p><p>&nbsp;</p><p><strong>Distribution </strong></p><p>The apparent volume of distribution of dolutegravir (Vd/F) is 17-20&nbsp;L. Intravenous studies with lamivudine showed that the mean apparent volume of distribution is 1.3&nbsp;L/kg.</p><p>&nbsp;</p><p>Dolutegravir is highly bound (&gt; 99%) to human plasma proteins based on <em>in vitro</em> data. Binding of dolutegravir to plasma proteins is independent of dolutegravir concentration. Total blood and plasma drug-related radioactivity concentration ratios averaged between 0.441 to 0.535, indicating minimal association of radioactivity with blood cellular components. The unbound fraction of dolutegravir in plasma is increased at low levels of serum albumin (&lt;35&nbsp;g/L) as seen in subjects with moderate hepatic impairment. Lamivudine exhibits linear pharmacokinetics over the therapeutic dose range and displays limited plasma protein binding <em>in vitro</em> (&lt;&nbsp;16%‑ 36% to serum albumin).</p><p>&nbsp;</p><p>Dolutegravir and lamivudine are present in cerebrospinal fluid (CSF). In 13 treatment-na&iuml;ve subjects on a stable dolutegravir plus abacavir/lamivudine regimen, dolutegravir concentration in CSF averaged 18&nbsp;ng/mL (comparable to unbound plasma concentration, and above the IC<sub>50</sub>). The mean ratio of CSF/serum lamivudine concentrations 2-4&nbsp;hours after oral administration was approximately 12%. The true extent of CNS penetration of lamivudine and its relationship with any clinical efficacy is unknown.</p><p>&nbsp;</p><p>Dolutegravir is present in the female and male genital tract. AUC in cervicovaginal fluid, cervical tissue and vaginal tissue were 6-10% of those in corresponding plasma at steady state. AUC in semen was 7% and 17% in rectal tissue of those in corresponding plasma at steady state.</p><p>&nbsp;</p><p><strong>Biotransformation</strong></p><p>Dolutegravir is primarily metabolized via UGT1A1 with a minor CYP3A component (9.7% of total dose administered in a human mass balance study). Dolutegravir is the predominant circulating compound in plasma; renal elimination of unchanged active substance is low (&lt; 1% of the dose). Fifty-three percent of total oral dose is excreted unchanged in the faeces. It is unknown if all or part of this is due to unabsorbed active substance or biliary excretion of the glucuronidate conjugate, which can be further degraded to form the parent compound in the gut lumen. Thirty-two percent of the total oral dose is excreted in the urine, represented by ether glucuronide of dolutegravir (18.9% of total dose), N-dealkylation metabolite (3.6% of total dose), and a metabolite formed by oxidation at the benzylic carbon (3.0% of total dose).</p><p>&nbsp;</p><p>Metabolism of lamivudine is a minor route of elimination. Lamivudine is predominately cleared by renal excretion of unchanged lamivudine. The likelihood of metabolic drug interactions with lamivudine is low due to the small extent of hepatic metabolism (5-10%).</p><p>&nbsp;</p><p><strong>Drug interactions</strong></p><p><em>In vitro</em>, dolutegravir demonstrated no direct, or weak inhibition (IC<sub>50</sub>&gt;50&nbsp;&mu;M) of the enzymes cytochrome P<sub>450</sub> (CYP)1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 CYP3A, UGT1A1 or UGT2B7, or the transporters Pgp, BCRP, BSEP, organic anion transporting polypeptide (OATP) 1B1, OATP1B3, OCT1, MATE2-K, multidrug resistance-associated protein (MRP) 2 or MRP4. <em>In vitro</em>, dolutegravir did not induce CYP1A2, CYP2B6 or CYP3A4. Based on this data, dolutegravir is not expected to affect the pharmacokinetics of medicinal products that are substrates of major enzymes or transporters (see section 4.5).</p><p><em>&nbsp;</em></p><p><em>In vitro</em>, dolutegravir was not a substrate of human OATP 1B1, OATP 1B3 or OCT 1.</p><p>&nbsp;</p><p><em>In vitro,</em> lamivudine did not inhibit or induce CYP enzymes (such as CYP3A4, CYP2C9 or CYP2D6) and demonstrated no or weak inhibition of OATP1B1, OAT1B3, OCT3, BCRP, P-gp, MATE1 or MATE2-K. Lamivudine is therefore not expected to affect the plasma concentrations of medicinal products that are substrates of these enzymes or transporters.</p><p>&nbsp;</p><p>Lamivudine was not significantly metabolised by CYP enzymes.</p><p><strong><u>&nbsp;</u></strong></p><p><strong>Elimination </strong></p><p>Dolutegravir has a terminal half-life of ~14&nbsp;hours. The apparent oral clearance (CL/F) is approximately 1&nbsp;L/hr in HIV-infected patients based on a population pharmacokinetic analysis.<!--[if supportFields]><span
style='mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"MS Mincho";mso-ansi-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_f5d40a4c-0d31-4453-9d6d-ed23f57aab37 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"MS Mincho";mso-ansi-language:EN-GB'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>The observed lamivudine half-life of elimination is 18 to 19&nbsp;hours. For patients receiving lamivudine 300&nbsp;mg once daily, the terminal intracellular half-life of lamivudine-TP was 16 to 19&nbsp;hours. The mean systemic clearance of lamivudine is approximately 0.32&nbsp;L/h/kg, predominantly by renal clearance (&gt;&nbsp;70%) via the organic cationic transport system. Studies in patients with renal impairment show lamivudine elimination is affected by renal dysfunction. Dose reduction is required for patients with creatinine clearance &lt;&nbsp;30&nbsp;mL/min (see section 4.2).</p><p><strong>&nbsp;</strong></p><p><strong>Pharmacokinetic/pharmacodynamic relationship(s)</strong></p><p>In a randomized, dose-ranging trial, HIV‑1&ndash;infected subjects treated with dolutegravir monotherapy (ING111521) demonstrated rapid and dose-dependent antiviral activity, with mean decline in HIV-1 RNA of 2.5&nbsp;log<sub>10</sub> at day 11 for 50&nbsp;mg dose. This antiviral response was maintained for 3 to 4 days after the last dose in the 50&nbsp;mg group.</p><p>&nbsp;</p><p><strong>Special patient populations</strong></p><p><strong>Children</strong></p><p>The pharmacokinetics of dolutegravir in 10 antiretroviral treatment-experienced HIV-1 infected adolescents (12 to 17&nbsp;years) showed that dolutegravir 50&nbsp;mg once daily dosage resulted in dolutegravir exposure comparable to that observed in adults who received dolutegravir 50&nbsp;mg once daily.</p><p>&nbsp;</p><p>Limited data are available in adolescents receiving a daily dose of 300&nbsp;mg of lamivudine. Pharmacokinetic parameters are comparable to those reported in adults.</p><p>&nbsp;</p><p><strong>Elderly</strong></p><p>Population pharmacokinetic analysis of dolutegravir using data in HIV-1 infected adults showed that there was no clinically relevant effect of age on dolutegravir exposure.</p><p>&nbsp;</p><p>Pharmacokinetic data for dolutegravir and lamivudine in subjects &gt;65 years of age are limited.</p><p>&nbsp;</p><p><strong>Renal impairment</strong></p><p>Pharmacokinetic data have been obtained for dolutegravir and lamivudine separately.</p><p>&nbsp;</p><p>Renal clearance of unchanged active substance is a minor pathway of elimination for dolutegravir. A study of the pharmacokinetics of dolutegravir was performed in subjects with severe renal impairment (CLcr&nbsp;&lt;30&nbsp;mL/min). No clinically important pharmacokinetic differences between subjects with severe renal impairment (CLcr &lt;30&nbsp;mL/min) and matching healthy subjects were observed. Dolutegravir has not been studied in patients on dialysis, though differences in exposure are not expected.</p><p>&nbsp;</p><p>Studies with lamivudine show that plasma concentrations (AUC) are increased in patients with renal dysfunction due to decreased clearance.</p><p>&nbsp;</p><p>Based on the lamivudine data, Dovato is not recommended for patients with creatinine clearance of &lt;&nbsp;30&nbsp;mL/min.</p><p><u>&nbsp;</u></p><p><strong>Hepatic impairment</strong></p><p>Pharmacokinetic data has been obtained for dolutegravir and lamivudine separately.</p><p>&nbsp;</p><p>Dolutegravir is primarily metabolized and eliminated by the liver. A single dose of 50&nbsp;mg of dolutegravir was administered to 8 subjects with moderate hepatic impairment (Child-Pugh class B) and to 8 matched healthy adult controls. While the total dolutegravir concentration in plasma was similar, a 1.5 to 2&nbsp;fold increase in unbound exposure to dolutegravir was observed in subjects with moderate hepatic impairment compared to healthy controls. No dosage adjustment is considered necessary for patients with mild to moderate hepatic impairment. The effect of severe hepatic impairment on the pharmacokinetics of dolutegravir has not been studied.</p><p>&nbsp;</p><p>Data obtained in patients with moderate to severe hepatic impairment show that lamivudine pharmacokinetics are not significantly affected by hepatic dysfunction.</p><p>&nbsp;</p><p><em>Polymorphisms in drug metabolising enzymes</em></p><p>There is no evidence that common polymorphisms in drug metabolising enzymes alter dolutegravir pharmacokinetics to a clinically meaningful extent. In a meta-analysis using pharmacogenomics samples collected in clinical studies in healthy subjects, subjects with UGT1A1 (n=7) genotypes conferring poor dolutegravir metabolism had a 32% lower clearance of dolutegravir and 46% higher AUC compared with subjects with genotypes associated with normal metabolism via UGT1A1 (n=41).</p><p>&nbsp;</p><p><strong>Gender</strong></p><p>Population PK analyses using pooled pharmacokinetic data from clinical studies where dolutegravir or lamivudine was administered to adults in combination with other ARVs revealed no clinically relevant effect of gender on the exposure of dolutegravir or lamivudine. There is no evidence that a dose adjustment of dolutegravir or lamivudine would be required based on the effects of gender on PK parameters.</p><p><u>&nbsp;</u></p><p><strong>Race </strong></p><p>Population PK analyses using pooled pharmacokinetic data from clinical studies where dolutegravir was administered to adults in combination with other ARVs revealed no clinically relevant effect of race on the exposure of dolutegravir. The pharmacokinetics of dolutegravir following single dose oral administration to Japanese subjects appear similar to observed parameters in Western (US) subjects. There is no evidence that a dose adjustment of dolutegravir or lamivudine would be required based on the effects of race on PK parameters.</p><p><u>&nbsp;</u></p><p><strong>Co-infection with Hepatitis B or C </strong></p><p>Population pharmacokinetic analysis indicated that hepatitis C virus co-infection had no clinically relevant effect on the exposure to dolutegravir. There are limited pharmacokinetic data on subjects with hepatitis B co-infection (see section 4.4).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no data available on the effects of the combination of dolutegravir and lamivudine in animals.</p><p>&nbsp;</p><p><strong>Carcinogenesis and mutagenesis</strong></p><p>Dolutegravir was not mutagenic or clastogenic using <em>in vitro</em> tests in bacteria and cultured mammalian cells, and an <em>in viv</em>o rodent micronucleus assay. Lamivudine was not mutagenic in bacterial tests, but consistent with other nucleoside analogues, inhibits cellular DNA replication in <em>in vitro</em> mammalian tests such as the mouse lymphoma assay. The results from two in vivo rat micronucleus tests with lamivudine were negative. Lamivudine has not shown any genotoxic activity in the <em>in vivo</em> studies.<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_12253313-02ec-4486-86bc-b01d0592ff7a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>The carcinogenic potential of a combination of dolutegravir and lamivudine has not been tested. Dolutegravir was not carcinogenic in long term studies in the mouse and rat. In long-term oral carcinogenicity studies in rats and mice, lamivudine did not show any carcinogenic potential.</p><p>&nbsp;</p><p><strong>Reproductive toxicology studies</strong></p><p>In reproductive toxicity studies in animals, dolutegravir and lamivudine were shown to cross the placenta.</p><p>&nbsp;</p><p>Oral administration of dolutegravir to pregnant rats at doses up to 1000&nbsp;mg/kg daily from days 6 to 17 of gestation did not elicit maternal toxicity, developmental toxicity or teratogenicity (37.2&nbsp;times the 50&nbsp;mg human clinical exposure, based on AUC following single dose in the fasted state). Oral administration of dolutegravir to pregnant rabbits at doses up to 1000&nbsp;mg/kg daily from days 6 to 18 of gestation did not elicit developmental toxicity or teratogenicity (0.55&nbsp;times the 50&nbsp;mg human clinical exposure, based on AUC following single dose in the fasted state). In rabbits, maternal toxicity (decreased food consumption, scant/no faeces/urine, suppressed body weight gain) was observed at 1000&nbsp;mg/kg (0.55&nbsp;times the 50&nbsp;mg human clinical exposure, based on AUC following single dose in the fasted state).</p><p>&nbsp;</p><p>Lamivudine was not teratogenic in animal studies but there were indications of an increase in early embryonic deaths in rabbits at relatively low systemic exposures, comparable to those achieved in humans. A similar effect was not seen in rats even at very high systemic exposure.</p><p>&nbsp;</p><p>Fertility studies in rats have shown that dolutegravir or lamivudine have no effect on male or female fertility.</p><p>&nbsp;</p><p><strong>Repeated dose toxicity</strong></p><p>The effect of prolonged daily treatment with high doses of dolutegravir has been evaluated in repeat oral dose toxicity studies in rats (up to 26&nbsp;weeks) and in monkeys (up to 38&nbsp;weeks). The primary effect of dolutegravir was gastrointestinal intolerance or irritation in rats and monkeys at doses that produce systemic exposures approximately 28.5 and 1.1&nbsp;times the 50&nbsp;mg human clinical exposure following single dose in the fasted state based on AUC, respectively. Because gastrointestinal (GI) intolerance is considered to be due to local active substance administration, mg/kg or mg/m<sup>2</sup> metrics are appropriate determinates of safety cover for this toxicity. GI intolerance in monkeys occurred at 30&nbsp;times the human mg/kg equivalent dose (based on 50&nbsp;kg human), and 11&nbsp;times the human mg/m<sup>2</sup> equivalent dose for a total daily clinical dose of 50&nbsp;mg.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Tablet core</strong></p><p>Microcrystalline cellulose</p><p>Sodium starch glycolate</p><p>Magnesium Stearate</p><p>Mannitol (E421)</p><p>Povidone (K29/32)</p><p>Sodium stearyl fumarate</p><p>&nbsp;</p><p><strong>Tablet coating</strong></p><p>Hypromellose (E464)</p><p>Macrogol</p><p>Titanium dioxide (E171)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Expiry date is indicated on the outer pack.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30 &deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Opaque, white HDPE (high density polyethylene) bottles closed with child resistant polypropylene closures, with a polyethylene faced induction heat seal liner. Each pack consists of one bottle containing 30 film-coated tablets.</p><p>&nbsp;</p><p>Not all presentations are available in every country.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p><em>Dovato</em> is<em> </em>trademark owned by or licensed to ViiV Healthcare group of companies</p><p>&copy;2025 ViiV Healthcare group of companies. All rights reserved.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by:
GlaxoSmithKline LLC, 1011 North Arendell Avenue Zebulon, North Carolina 27597

Packed by:
Glaxo Wellcome, S.A*. Avda. Extremadura, 3
09400 Aranda De Duero, Burgos, Spain

Marketing Authorisation Holder:
Glaxo Saudi Arabia Ltd.* Jeddah, KSA
Address: P.O. Box 22617 Jeddah 21416 – Kingdom of Saudi Arabia

*member of the GlaxoSmithKline group of companies
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Version number: EMEAv20

Date of issue: 31 October 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>